INDEX

Volume Twenty-Five—January through December 1991

DICP, The Annals of Pharmacotherapy

JANUARY	Pages 1–114
FEBRUARY	Pages 115–226
MARCH	Pages 227–338
APRIL	Pages 339–450
MAY	Pages 451–572
JUNE	Pages 573–702
JULY/AUGUST	Pages 703–906
SEPTEMBER	Pages 907–1038
OCTOBER	Pages 1039–1158
NOVEMBER	Pages 1159–1294
DECEMBER	Pages 1295–1444

SUBJECT INDEX

A

Abate, Marie A., USPC drug information development programs (NC) 450
Absorption, acetylcysteine, activated charcoal (TC) 1081; digoxin, quinidine, interaction, sucralfate (SR) 745; lidocaine, age (SR) 463
Academy of Students of Pharmacy, see **Association News (NC)**
Acebutolol, beta-adrenergic receptor response, racial groups (A) 827; pharmacokinetics (DSP) 965; pharmacology (DSP) 962
Acetazolamide, confused with acetohexamide (L) 100
Acetoacetate, biochemical marker, nutrition support (A) 265
Acetohexamide, confused with acetazolamide (L) 100
Acetylcholine, intraocular, hypotension, bradycardia (CR) 1178
Acetylcysteine, absorption, activated charcoal (TC) 1081
Actisomide, pharmacokinetics, tolerance (RPR) 231
Acyclovir, compared with foscarnet sodium (FF) 43; no interaction, cyclosporine (L) 316; utilization (PEP) 1374
Addiction, see **Dependence**
Adenosine, compared with verapamil, supraventricular tachycardia (DIAS) 749; stress testing (FF) 1089
Adrenocorticotropic hormone, myasthenia gravis (A) 1105
Age, lidocaine absorption (SR) 463; lymphocyte β_2-adrenergic receptor responsiveness (A) 532
Agranulocytosis, enalapril (CR) 461; erythromycin (L) 1136
AIDS, clofazimine, *Mycobacterium avium* (FF) 528; cost, outpatient (PEC) 414; counseling, testing services (NC) 1430; cytomegalovirus, foscarnet sodium, review (FF) 41; dextran (DIAS) 606; FDA position (RC) 428; home care (A) 847; incidence, Europe (NC) 114, women (NC) 114; mortality (NC) 338; pentamidine, nephrotoxicity, hyperkalemia (RPR) 1171; *Pneumocystis carinii* pneumonia, trimethoprim/sulfamethoxazole (DIAS) 941
Albumin, admixture, parenteral nutrition (CC) 278; utilization, physician intervention (RPR) 239
Albuterol, see also, **Volmax**
Allergy, clindamycin (L) 317; phenytoin (CR) 929
Alprostadil, congenital heart disease, neonatal transport (PED) 408; impotence (DIAS) 363
Alteplase, administration delay, myocardial infarction (A) 1098; compared with streptokinase (L) 1271; neonatal thrombosis (PED) 853
Altretamine, adverse reactions (FF) 150; pharmacokinetics (FF) 147; pharmacology (FF) 147; review (FF) 146
Aluminum hydroxide, kidney failure (DIAS) 943
Amantadine, cocaine abuse (A) 820; neurotoxicity, renal transplant (CR) 1175
Ambenonium chloride, myasthenia gravis (A) 1103
Ambulatory care, cost, compared with disease progression, HIV population (PEC) 414; drug information, penicillin (RPR) 925; prescribing patterns, geriatrics (G) 186, Saudi Arabia (IR) 90; psychotherapeutic prescriptions (PEP) 85
American Association of Colleges of Pharmacy, see **Association News (NC)**
American College of Clinical Pharmacy, see **Association News (NC)**
American Council on Pharmaceutical Education, see **Association News (NC)**
American Pharmaceutical Association, see **Association News (NC)**
Amikacin, postantibiotic effect (A) 156
Amiloride, compared with felodipine (FF) 1198; lung disease, cystic fibrosis (DIAS) 1340
Amino acids, biochemical markers, nutrition support (A) 265
Aminoglycosides, conversion to ceftriaxone, cost (L) 319; dosage schedules (L) 558; pharmacokinetics, two- vs. three-point method (TM) 635, (L) 1141; postantibiotic effect (A) 154; with beta-lactams, synergy (A) 972
Aminophylline, admixture, parenteral nutrition (CC) 279
Aminosalicylic acid, availability (NC) 1430
Amitriptyline, compared with sertraline (FF) 954; pharmacokinetics (TM) 1368
Amphotericin B, compatibility, magnesium sulfate (RPR) 123; hepatotoxicity (L) 559
Ampicillin, postantibiotic effect (A) 155
Amrinone, congestive heart failure, review (A) 1352
Analgesia, meperidine, concentrations, postoperative (RPR) 724; vapreotide (L) 1136
Anaphylaxis, tetanus toxoid (L) 870; vitamin K_1 (L) 871
Anesthesia, neuromuscular blocking agents, pharmacology (A) 54
Angina pectoris, felodipine, review (FF) 1199
Angioplasty, dipyridamole (DIAS) 747
Angiotensin-converting enzyme inhibitors, congestive heart failure, review (A) 1349
An Opinion, see also, **Editorials; Coulston, Daniel R.,** Hepatitis B Vaccine, 671; **Galinsky, Raymond E., Nickman, Nancy A.,** Pharmacists and the Mandate of Pharmaceutical Care, 431; **Green, Jeffrey A.,** The Healthcare Professional of the Future: Function Based upon Competence, 205; **Hatoum, Hind T., Vlasses, Peter H.,** Patient Outcome and the Future Practice of Pharmacy, 208; **Vitillo, Josephine A., Lesar, Timothy S.,** Preventing Medication Prescribing Errors, 1388; **Vree, Tom B.,** Pharmacist–Physician Interaction: A Battle of Genes, 1132
Antacids, interaction, ciprofloxacin, review (DIAS) 473, quinolones (DIR) 1250
Antibiotics, dosing frequencies, cost (PEC) 546; parenteral, compared with oral ciprofloxacin (PEP) 857; postantibiotic effect (A) 153; prophylaxis, coronary bypass surgery (TC) 478; restricted, utilization (IR) 662
Antibodies, monoclonal, E5, adverse reactions (FF) 788, pharmacokinetics (FF) 787, review (FF) 784; human, adverse reactions (FF) 781, pharmacokinetics (FF) 780, pharmacology (FF) 778, review (FF) 778
Anticonvulsants, pharmacokinetics (A) 979; vitamin E (DIAS) 362
Antidepressants, cocaine abuse (A) 818; tricyclic, pharmacokinetics (TM) 1368
Antiinflammatory drugs, asthma, review (PA) 998; nonsteroidal, CNS toxicity (CR) 1066, generic–brand name knowledge (L) 1138, package inserts, Saudi Arabia compared with US (IR) 863
Antipsychotics, cocaine abuse (A) 821
Aortic dissection, acute, esmolol (CR) 735
Apnea, phenothiazine (CR) 244
Arrhythmia, famotidine (L) 315
Arthritis, rheumatoid, hydroxychloroquine pharmacokinetics (RPR) 1302
Aspirin, administration delay, myocardial infarction (A) 1096; compared with dipyridamole, angioplasty (DIAS) 747; glucose-6-phosphate dehydrogenase deficiency (SR) 1074; topical, postherpetic neuralgia (DIAS) 1077
Association News (NC), AACP 1990-91 GAPS Awards, 572; AACP Faculty Salary Survey, 701; ACCP Election Results, 226; ACCP Issues Guidelines for Clinical Pharmacokinetics Service, 1037; ACCP Pharmacotherapy Self-Assessment Program, 1037; ACCP Position on Entry-Level Degree for Pharmacy, 572; ACPE Intent to Revise Standards—Status Report, 905; APhA comments on Medicare Home Drug Infusion, 1432; APhA Joined by NCL for a Third Class of Drugs, 905; APhA-ASP Task Force on Revision of Accreditation and Standards Guidelines, 1157; BPS Certification Examination for Nutrition Support on Schedule, 905; BPS Completes Pharmacotherapy Validation Exercise, 905; BPS Pharmacotherapy Examination Developed; Psychopharmacy Petition Received, 226; BPS Sets Nutrition Certification Requirements, 1038; Council on Student Affairs Founded, 1293; FIP Congress Pharmacy Information Section Program, 701; JCPP Needs Comments on Mission, 1037; NASCDS Commissioned Survey of Pharmacy School Faculty, 450; 19th European Symposium on Clinical Pharmacy, 226; Research Institute Awards $125 000 in Grants, 1430; Society of Infectious Diseases Pharmacists Founded, 450; Society of Infectious Diseases Pharmacists Incorporates, 1293
Asthma, corticosteroids, review (PA) 72; pathogenesis (PA) 993; patient education 638 (PA), (E) 668
Atenolol, alcohol withdrawal (DIAS) 31; beta-adrenergic receptor response, racial groups (A) 825; pharmacokinetics (DSP) 965; pharmacology (DSP) 962
Atracurium, pharmacodynamics (A) 59; pharmacokinetics (A) 59
Atropine, pediatric cardiopulmonary resuscitation (TC) 766
Attention deficit disorder with hyperactivity, bupropion (DSP) 1209; clomipramine (DSP) 1209; clorgiline (DSP) 1209; dextroamphetamine (DSP) 1207; imipramine (DSP) 1207; methylphenidate (DSP) 1208; review (DSP) 1207; tranylcypromine (DSP) 1209
Azathioprine, myasthenia gravis (A) 1105
Azlocillin, postantibiotic effect (A) 155
Aztreonam, myelosuppression (CR) 594; postantibiotic effect (A) 154

B

Bacillus Calmette-Guerin vaccine, adverse reactions, review (A) 1361; superficial bladder cancer, review (A) 1355
Bacteria, susceptibility, cefmenoxime, ciprofloxacin, tobramycin, pharmacokinetics (RPR) 1050
Baker, Danial E., USPC drug information development programs (NC) 450
BCG, see **Bacillus Calmette-Guerin vaccine**
Beck, Diane E., AACP Lyman Award (NC) 572
Belgium, package inserts (IR) 1002
Benet, Leslie Z., AACP Volwiler Research Achievement (NC) 572
Benzodiazepines, alcohol withdrawal (DIAS) 31; utilization (PEP) 1374

Beta-blockers, see **Sympatholytic agents**
Beta-hydroxybutyrate, biochemical marker, nutritional support (A) 267
Beta-lactam agents, synergy (A) 972
Betamethasone, compared with hydrocortisone, dexamethasone, asthma (PA) 73
Betaxolol, pharmacokinetics (DSP) 965
Bezafibrate, rhabdomyolysis (L) 869
Binding, protein, vancomycin, *Staphylococcus aureus* (RPR) 713
Bioavailability, see **Drugs, availability**
Biochemical markers, nutrition support (A) 265
Biologic response modifiers, cancer (DSP) 490
BIOSIS, compared with EMBASE, TOXLINE, MEDLINE, IDIS, Core MEDLINE, PASCAL, PHARMLINE, IPA, adverse drug reactions (RPR) 1062
Biotransformation, phenytoin, teratogenicity (PED) 987
Bisoprolol, clearance, kidney failure (A) 1219
Bleeding, gastrointestinal, pentoxifylline (L) 315
Bleomycin, cell lethality, containers (RPR) 14; compared with talc, malignant pleural effusion (DIAS) 1188
Blepharitis, chronic, I-Scrub (SR) 359
Blood levels, see **Concentrations**
Blood pressure, phenylpropanolamine–indomethacin (RPR) 234
Board of Pharmaceutical Specialties, see **Association News (NC)**
Book Reviews, Atherosclerosis Reviews: Prevention and Noninvasive Therapy of Atherosclerosis (A. Leaf, P.C. Weber), 683; Bioadhesion: Possibilities and Future Trends (R. Gurny, H.E. Junginger), 323; Biopharmaceutics and Clinical Pharmacokinetics (M. Gibaldi), 104; Cardiovascular Pharmacology, 3rd Edition, 440; Chemotherapy of Gynecologic Cancer, 2nd Edition (G. Deppe), 1144; Clinical Drug Therapy: Rationales for Nursing Practice, 3rd. Edition (A.C. Abrams), 1018; CYBERLOG: A Library of Applied Medical Software: Arrhythmias (A.K. Almquist), 683; Drug Regimen Review: A Process Guide for Pharmacists (W.G. Erwin), 105; Drug Safety in Pregnancy (P.I. Folb, M.N.G. Dukes), 1017; Drug Therapy in Emergency Medicine (J.P. Ornato, E.R. Gonzalez), 216; Early Phase Drug Evaluation in Man (J.O. Grady, O.I. Linet), 1275; Effects of Drugs on Clinical Laboratory Tests, 3rd Edition (D.S. Young), 1017; Generic Drugs: A Guide to FDA Approval Requirements, 2nd Edition (D.O. Beers), 879; Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Edition (A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor), 1401; Handbook of Nonprescription Drugs, 9th Edition, 322; Handbook on Injectable Drugs, 6th Edition (L.A. Trissel), 1144; Handbook of Pharmacy Health-Care: Diseases and Patient Advice (R.J. Harman), 1402; Infections in Intravenous Drug Abusers (D.P. Levine, J.D. Sobel), 1401; Infectious Diseases: Prophylaxis & Chemotherapy (J. Schneider, J. Hugher, H. Henderson), 878; Inside the Drug Industry (B. Spilker, P. Cuatrecasas), 683; Medical Informatics: Computer Applications in Health Care (E.H. Shortliffe, L.E. Perreault), 105; Oral Controlled Release Products: Therapeutic and Biopharmaceutic Assessment (E.Gundert-Remy, H. Moller), 216; Patient Compliance in Medical Practice and Clinical Trials (J.A. Cramer, B. Spilker), 1144; Pediatric Drug Formulations (M.C. Nahata, T.F. Hipple), 104; Percutaneous Antirheumatic Therapy: A Reappraisal (K. Brune), 217; Pharmacy: An Illustrated History (D.L. Cowen, W.H. Helfand), 683; Principles of Drug Action: The Basis of Pharmacology, 3rd. Edition (W.B. Pratt, P. Taylor), 216; Syllabus for the Review Course in Addiction Medicine (B.B. Wilford), 878; Testing and Evaluation of Drugs of Abuse (M.W. Adler, A. Cowan), 322; Textbook of Secretory Diarrhea (E. Leventhal, M.E. Duffey), 1275; The New Generation of Quinolones (C. Siporin, C.L. Heifetz, J.M. Domagala), 560; Treatment of Chronic Pain: Possibilities, Limitations and Long-term Follow-up, 439
Books Received, 106, 217, 324, 440, 561, 684, 879, 1018, 1145, 1276, 1402
Brachial plexus palsy, geriatric chair, haloperidol (SR) 1072
Bradycardia, acetylcholine, intraocular (CR) 1178; nimodipine (CR) 247
Bretylium, pediatric cardiopulmonary resuscitation (TC) 768
Bromocriptine, cocaine abuse (A) 820; compared with selegiline, Parkinson's disease (FF) 38
Bronchodilators, review (PA) 997
Bufuralol, clearance, kidney failure (A) 1215
Bulimia, fluoxetine (DIAS) 254
Bupropion, attention deficit disorder with hyperactivity (DSP) 1209
Butofilolol, clearance, kidney failure (A) 1216

C

Caffeine, interaction, phenothiazine (L) 437
Caffeine sodium benzoate, electroconvulsive therapy (DIAS) 1079
Calcifediol, psoriasis (A) 835
Calcitonin, migraine (DIAS) 1185
Calcitriol, psoriasis (A) 835
Calcium, interaction, quinolones (DIR) 1252; pediatric cardiopulmonary resuscitation (TC) 766
Calcium, carbonate, kidney failure (DIAS) 945; citrate, kidney failure (DIAS) 943
Campbell, R. Keith, Washington State University Outstanding Alumni Award (NC) 1038
Cancer, biologic response modifiers, review (DSP) 490; bladder, BCG vaccine, review (A) 1355; ovarian, altretamine, review (FF) 146; pain management (A) 1225; prostate, goserelin acetate, review (FF) 796
Candidiasis, vulvovaginal, fluconazole compared with clotrimazole (RPR) 582
Capsaicin, adverse reactions (FF) 385; pharmacokinetics (FF) 383; pharmacology (FF) 382; review (FF) 381
Captopril, clearance, kidney failure (A) 1216; compared with quinapril (FF) 500
Carbamazepine, cocaine abuse (A) 820; monitoring, children (PED) 1109; with phenobarbital, acute water intoxication (CR) 354
Carbapenem agents, with beta-lactams, synergy (A) 975
Carbenicillin, postantibiotic effect (A) 155
Carmichael, Jannet M., president-elect, American Society of Hospital Pharmacists (NC) 1431
Carteolol, pharmacokinetics (DSP) 965; pharmacology (DSP) 963
Case Reports, see **Pharmacotherapy Case Reports**
Cations, interaction, quinolones (DIR) 1249
Cefamandole, postantibiotic effect (A) 156; prophylaxis, coronary bypass surgery (TC) 481
Cefazolin, postantibiotic effect (A) 156; prophylaxis, coronary bypass surgery (TC) 481
Cefmenoxime, pharmacokinetics, bacterial susceptibility (RPR) 1050
Cefoperazone, postantibiotic effect (A) 156
Cefotaxime, postantibiotic effect (A) 156
Cefotetan, compared with cefoxitin, surgical prophylaxis (RPR) 10
Cefoxitin, compared with cefotetan, surgical prophylaxis (RPR) 10
Cefpiramide, clearance, kidney failure (A) 1219
Ceftazidime, dosage schedule, elderly (G) 284; pharmacokinetics, elderly (G) 285; postantibiotic effect (A) 156; resistance, *Pseudomonas aeruginosa* (L) 871; thrombocytopenia (SR) 135
Ceftizoxime, pharmacokinetics, neonates, infants (RPR) 344
Ceftriaxone, conversion to aminoglycoside, cost (L) 319; nenonatal meningitis (SR) 27; postantibiotic effect (A) 156; stability, peritoneal dialysis (SR) 741; thrombocytopenia (SR) 135; utilization (L) 872
Cefuroxime, prophylaxis, coronary bypass surgery (TC) 481
Cefuroxime axetil, suspension, pediatrics (PED) 1236
Cephalosporins, postantibiotic effect (A) 154
Cephalothin, postantibiotic effect (A) 156
Cerebral blood flow, dynamic, enalapril, prazosin (RPR) 1299
Charcoal, activated, acetylcysteine absorption (TC) 1081, pharmacokinetics, phenytoin poisoning (PED) 646
Chloramphenicol, postantibiotic effect (A) 154
Chlordiazepoxide, alcohol withdrawal (DIAS) 31; compared with propranolol, alcohol withdrawal (DIAS) 32
Chlormezanone, fixed drug eruption (SR) 604
Cholecalciferol, psoriasis, review (A) 835
Cholera, incidence (NC) 1294
Cholestyramine, compared with simvastatin (FF) 260
Cholinergic antagonists, asthma (PA) 998
Cholinesterase inhibitors, myasthenia gravis (A) 1103
Cilastatin, with imipenem, drug usage evaluation (RPR) 348, (L) 1399; seizures (CR) 351
Cilazapril, clearance, kidney failure (A) 1220
Cimetidine, epidural morphine pruritus (RPR) 716; idiopathic urticaria (DIAS) 609
Ciprofloxacin, interaction, antacids, review (DIAS) 473, cations (DIR) 1250, sucralfate (RPR) 578, theophylline, computer monitoring (L) 1011, warfarin (L) 1397; mycobacterial infections (RPR) 919; oral, compared with parenteral antibiotics (PEP) 857; pharmacokinetics, bacterial susceptibility (RPR) 1050
Citrobacter freundii, meningitis, neonates, ceftriaxone (SR) 27
Clayton, Anne G., AACP Lyman Award (NC) 572
Clearance, see **Excretion**
Clindamycin, hypersensitivity (L) 317; postantibiotic effect (A) 154
Clinical studies, altretamine (FF) 147; anticonvulsants (A) 979; capsaicin (FF) 384; clofazimine (FF) 526; dipyridamole (FF) 1087; E5 monoclonal antibody (FF) 786; felodipine (FF) 1196; fludarabine (FF) 520; foscarnet (FF) 43; goserelin acetate (FF) 798; human monoclonal antibody (FF) 780; idarubicin (FF) 507; immune globulin (DSP) 809, (DSP) 810; ketoconazole (A) 395; mesalamine (FF) 141; ondansetron (FF) 370; pegademase bovine (FF) 1094; pravastatin (FF) 390; quinapril (FF) 500; selegiline (FF) 36; sertraline (FF) 954; simvastatin (FF) 259; vitamin D (A) 836
Clofazimine, adverse reactions (FF) 529; compared with dapsone (FF) 527; interaction, isoniazid, review (FF) 530; pharmacokinetics (FF) 526; pharmacology (FF) 525; review (FF) 525
Clomipramine, attention deficit disorder with hyperactivity (DSP) 1209
Clonazepam, mania (SR) 938
Clonidine, growth acceleration (DIAS) 1339, (E) 1384
Clorgiline, attention deficit disorder with hyperactivity (DSP) 1209
Clotrimazole, compared with fluconazole, vulvovaginal candidiasis (RPR) 582; utilization (PEP) 1374
Cloxacillin, postantibiotic effect (A) 155
Cocaine, abuse, amantadine (A) 820, bromocriptine (A) 820, carbamazepine (A) 820, desipramine (A) 818, flupenthixol decanoate (A) 821, imipramine (A) 819, lithium (A) 821, maprotiline (A) 819, methylphenidate hydrochloride (A) 820, monoamine oxidase inhibitors (A) 820, trazodone (A) 819, treatment, review (A) 818, tyrosine (A) 820
Codeine, clearance, kidney failure (A) 1219; recovering alcoholic, addict (A) 49; utilization (PEP) 1374
Colchicine, halothane hepatitis (L) 211
Colistin, toxicity, cystic fibrosis (RPR) 1168
Colitis, ulcerative, mesalamine (L) 1015, review (FF) 140
Colony-stimulating factors, cancer (DSP) 490; pharmacokinetics (DSP) 491; toxicity (DSP) 492
Compatibility, see **Incompatibility**
Compliance, digoxin, concentration (L) 103; phenytoin, concentration (L) 103; subtherapeutic concentrations (L) 1016
Computers, monitoring, ciprofloxacin–theophylline interaction (L) 1011
Concentrations, actisomide (RPR) 231; aminoglycosides (TM) 635; amitriptyline (TM) 1368; carbamazepine, children (PED) 1109; desipramine (TM) 1368; digoxin, assay anomalies (SR) 739, compliance (L) 103, Lanoxin vs. Lanoxicaps (RPR) 1043, with digoxin immune Fab (RPR) 1047; digoxin immune Fab, kidney failure (CR) 1315; doxepin (TM) 1368; gentamicin, postpartum endomyometritis (RPR) 1306; hydroxychloroquine, rheumatoid arthritis (RPR) 1302; 3-hydroxyquinidine (L) 867;imipramine (TM) 1368; meperidine, postoperative (RPR) 724; nortriptyline (TM) 1368; phenytoin, compliance (L) 103; procainamide, neonates (PED) 68; subtherapeutic, compliance (L) 1016; theophylline, compliance (L) 103; trimethoprim/sulfamethoxazole, *Pneumocystis carinii* pneumonia (DIAS) 941
Congestive heart failure, digoxin (L) 320; felodipine, review (FF) 1200
Containers, plastic, glass, bleomycin cell lethality (RPR) 14
Controlled Substances Act, cancer patients (A) 1229
Core MEDLINE, compared with EMBASE, TOXLINE, MEDLINE, BIOSIS, IDIS, PASCAL, PHARMLINE, IPA, adverse drug reactions (RPR) 1062
Corrections, see **Letters**
Corticosteroids, see **Steroids, cortico-**
Cortisone acetate, asthma (PA) 72
Costs, see **Pharmacoeconomics**
Council on Student Affairs, see **Association News (NC)**
Covington, Timothy R., pharmaceutical editor, *Handbook of Nonprescription Drugs* (NC) 1431
Critical Care Therapeutics, Charge and Reimbursement Analysis for Intensive Care Unit Patients in a Large Tertiary Teaching Hospital, 1231; Is There a Reliable Index of Glomerular Filtration Rate in Critically Ill Patients?, 169; Parenteral Nutrient Admixtures as Drug Vehicles: Theory and Practice in the Critical Setting, 276
Cromolyn sodium, asthma, review (PA) 998
Curare, pharmacodynamics (A) 57; pharmacokinetics (A) 58
Cyclophosphamide, myasthenia gravis (A) 1105
Cyclosporine, clearance, kidney failure (A) 1219;Graves'ophthalmopathy (DIAS) 750; interaction, erythromycin (DIAS) 30; myasthenia gravis (A) 1106; no interaction, acyclovir (L) 316; pharmacokinetics, plasmapheresis (L) 211
Cystic fibrosis, amiloride, lung disease (DIAS) 1340; colistin, toxicity (RPR) 1168; infection, home monitoring (A) 840; pancreatic enzymes, prescription drugs (NC) 1157; theophylline clearance (L) 212
Cytochrome P-450, phenytoin biotransformation (PED) 989
Cytomegalovirus, foscarnet sodium, review (FF) 41

D

Dapsone, compared with clofazimine (FF) 527
Databases, adverse drug reactions, comparison (RPR) 1062
Delirium, misoprostol (SR) 133
Dependence, cancer patients (A) 1226; codeine, recovering alcoholic, addict (A) 49
Depression, tricyclic antidepressants, Parkinson's disease (DIAS) 137
Desipramine, attention deficit disorder with hyperactivity (DSP) 1209; cocaine abuse (A) 818; pharmacokinetics (TM) 1368
Desmethyldiazepam, clearance, kidney failure (A) 1217
Dexamethasone, bacterial meningitis, infants, children (PED) 543; compared with hydrocortisone, betamethasone, asthma (PA) 73; compatibility, ondansetron (L) 869
Dextran, HIV inhibition (DIAS) 606
Dextroamphetamine, attention deficit disorder with hyperactivity (DSP) 1209; compared with imipramine, attention deficit disorder with hyperactivity (DSP) 1207
Dextrose, 5%, amphotericin B/magnesium sulfate compatibility (RPR) 123
Diabetes, foot infections, home care (A) 846
Dialysis, peritoneal, ceftriaxone sodium stability (SR) 741
DIAS Rounds, Adenosine in Supraventricular Tachycardia, 749; Adverse Effects of Sustained-Release Niacin, 253; Alprostadil in Impotence, 363; Amiloride for Lung Disease in

Cystic Fibrosis, 1340; Aseptic Meningitis and Muromonab-CD3 Therapy, 138; Caffeine in Electroconvulsive Therapy, 1079; Calcitonin in Migraine, 1185; Calcium Carbonate in Hyperphosphatemia, 945; Cimetidine in Idiopathic Urticaria, 609; Clonidine for Growth Acceleration, 1339; Cyclosporine in Graves' Ophthalmopathy, 750; Depression Treatment in Parkinson's Disease, 137; Dextran Inhibition of Human Immunodeficiency Virus, 606; Dipyridamole in Angioplasty, 747; Erythromycin and Cyclosporine Drug Interaction, 30; Fluoxetine and Suicidal Ideation, 607; Fluoxetine in Bulimia, 254; Granulocyte-Macrophage Colony-Stimulating Factor in Neutropenia, 32; history (SC) 306; Ketamine and Succinylcholine for Emergency Intubation of Pediatric Patients, 475; Midazolam Routes of Administration, 476; Niacinamide for Bullous Pemphigoid, 1187; Phosphate Binders in Hyperphosphatemia of Chronic Renal Failure, 942; Significance of the Ciprofloxacin–Antacid Interaction, 473; Talc in the Treatment of Malignant Pleural Effusion, 1187; Topical Aspirin for Postherpetic Neuralgia, 1077; Topical Uses of Testosterone, 1341; Trimethoprim/Sulfamethoxazole Concentrations in *Pneumocystis carinii* Pneumonia, 941; Verapamil as Migraine Prophylaxis, 1076; Verapamil in Premenstrual Syndrome, 361; Vitamin D in Psoriasis, 753; Vitamin E as an Anticonvulsant, 362

Diazepam, alcohol withdrawal (DIAS) 31

Dicloxacillin, postantibiotic effect (A) 155

DICP, The Annals of Pharmacotherapy, 25th anniversary (E) 97; Francke, Donald E., biographical sketch (SC) 425; history, DIAS Rounds (SC) 307; pediatric information, review articles (L) 559

Diethylstilbestrol, compared with goserelin acetate (FF) 799

Digoxin, concentrations, compliance (L) 103, with digoxin immune Fab (RPR) 1047; congestive heart failure (L) 320, review (A) 1350; dissociation, digoxin immune antibody, kidney failure (L) 1269; Lanoxin vs. Lanoxicaps (RPR) 1043; with quinidine/warfarin, interaction, sucralfate (SR) 745

Digoxin immune Fab, digoxin assay anomalies (SR) 739; digoxin concentrations (RPR) 1047; digoxin dissociation, kidney failure (L) 1269; pharmacokinetics, kidney failure (CR) 1315

5',5'-Dihydrofolic acid reductase, phenytoin biotransformation (PED) 989

Dilevalol, beta-adrenergic receptor response, racial groups (A) 827

Diphenhydramine, toxicity, varicella zoster (CR) 130

Dipyridamole, compared with aspirin, angioplasty (DIAS) 747; pharmacodynamics (FF) 1086; pharmacokinetics (FF) 1086; review (FF) 1085

Diuretics, congestive heart failure, review (A) 1350; potassium-sparing vs. potassium supplements (L) 439

Dobutamine, congestive heart failure, review (A) 1352; pediatric cardiopulmonary resuscitation (TC) 767

Dopamine, pediatric cardiopulmonary resuscitation (TC) 767

Dosage, aminoglycosides, pharmacokinetics, two- vs. three-point method (L) 1141; corticosteroids, asthma (PA) 77; epinephrine, cardiopulmonary resuscitation (TC) 773; frequency, antibiotics, cost (PEC) 546; isosorbide dinitrate (L) 1272; theophylline, pediatrics (PED) 179; tranylcypromine sulfate, MAO inhibition (L) 99

Dosage form, endotracheal, pediatric cardiopulmonary resuscitation (TC) 761; **epidural,** morphine, pruritus (RPR) 716; **extended-release tablets,** gastric obstruction (L) 678; **gel,** compared with suppository, prostaglandin E$_2$ (RPR) 456; **gum,** nicotine (RPR) 730; **inhalers,** metered-dose (PA) 638; **intraocular,** acetylcholine (CR) 1178; **intraosseous,** pediatric cardiopulmonary resuscitation (TC) 762; **intraperitoneal,** vancomycin (SR) 602; **intravenous,** compared with intramuscular, teicoplanin (RPR) 914, conversion to oral, ranitidine (SR) 251, dipyridamole (FF) 1085, enalaprilat (SR) 25; **nebulized,** ventilator parameters, neonates (PED) 272; **oral,** ciprofloxacin, compared with parenteral antibiotics (PEP) 857, conversion to intramuscular depot, formulation (L) 1270; **parenteral,** conversion to oral, H$_2$-receptor antagonist (PEC) 80; **suspension,** cefuroxime axetil, pediatrics (PED) 1236; **sustained-release,** niacin, adverse reactions (DIAS) 253, (L) 1014; **tablets,** digoxin, compared with capsules (RPR) 1043; **topical,** aspirin, postherpetic neuralgia (DIAS) 1077, testosterone (DIAS) 1341

Dosage schedule, aminoglycosides (L) 558; ceftazidime, elderly (G) 284; plicamycin (L) 215

Doxepin, pharmacokinetics (TM) 1368

Doxorubicin, superficial bladder cancer (A) 1357

Drug abuse, cocaine, treatment, review (A) 818

Drug administration, antibiotics, cost (PEC) 546; delay, thrombolytic agents, myocardial infarction (A) 1096; hepatitis B vaccine (A) 628; human growth hormone, Nordiject (RPR) 585; intravenous, methylprednisolone acetate (L) 436; midazolam (DIAS) 476; parenteral nutrition, review (CC) 276

Drug information, adverse drug reactions, database comparison (RPR) 1062; elderly (G) 410; impact on prescribing practices (L) 102; manual vs. computer-based literature search (L) 214, (L) 875; package inserts, Belgium (IR) 1002; penicillin, outpatients (RPR) 925; Zimbabwe, establishment (IR) 1379

Drug interactions, acyclovir–cyclosporine, none (L) 316
- antacids–ciprofloxacin, review (DIAS) 473
- beta-lactams, synergy (A) 972
- caffeine–phenothiazine (L) 437
- cations–quinolones, review (DIR) 1249
- ciprofloxacin–antacids, review (DIAS) 473
- ciprofloxacin–sucralfate (RPR) 578
- ciprofloxacin–warfarin (L) 1397
- clofazimine–isoniazid, review (FF) 530
- cyclosporine–acyclovir, none (L) 316
- cyclosporine–erythromycin (DIAS) 30
- digoxin–sucralfate (SR) 745
- erythromycin–cyclosporine (DIAS) 30
- erythromycin–felodipine (L) 1007
- felodipine–erythromycin (L) 1007
- felodipine, review (FF) 1202
- fluoxetine–imipramine (L) 1273
- fluoxetine, review (DIR) 657
- imipramine–fluoxetine (L) 1273
- indomethacin–phenylpropanolamine, none (RPR) 234
- isoniazid–clofazimine, review (FF) 530
- lisinopril–lithium (L) 101
- lithium–lisinopril (L) 101
- mexiletine–theophylline (RPR) 727
- nafcillin–warfarin (CR) 598
- pegademase bovine–pentostatin, review (FF) 1094
- pegademase bovine–vidarabine, review (FF) 1094
- pentostatin–pegademase bovine, review (FF) 1094
- phenothiazine–caffeine (L) 437
- phenylpropanolamine–indomethacin, none (RPR) 234
- phenytoin–tizanidine (L) 1273
- piperacillin–tobramycin (SR) 357
- pravastatin, review (FF) 392
- quinidine–sucralfate (SR) 745
- quinolones–cations, review (DIR) 1249
- quinolones–theophylline, meta-analysis (DIR) 191
- ranitidine–theophylline (CR) 21, (L) 1139
- sertraline, review (FF) 958
- sucralfate–ciprofloxacin (RPR) 578
- sucralfate–digoxin (SR) 745
- sucralfate–quinidine (SR) 745
- sucralfate–warfarin (SR) 745
- theophylline–mexiletine (RPR) 727
- theophylline–quinolones, meta-analysis (DIR) 191
- theophylline–ranitidine (CR) 21, (L) 1139
- tizanidine–phenytoin (L) 1273
- tobramycin–piperacillin (SR) 357
- vidarabine–pegademase bovine, review (FF) 1094
- warfarin–ciprofloxacin (L) 1397
- warfarin–nafcillin (CR) 598
- warfarin–sucralfate (SR) 745

Drug Interactions and Reactions Update, Adverse Effects and Drug Interactions Associated with Fluoxetine Therapy, 657 Meta-Analysis of Quinolone–Theophylline Interactions, 191 Quinolone–Cation Interactions: A Review, 1249

Drug Selection Perspectives, Around the Beta-Blockers, One More Time, 962; Clinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview. Part II. Colony-Stimulating Factors and Interleukin-2, 490; Treatment of Attention Deficit Hyperactivity Disorder: A Critical Review, 1207; Use of Intravenous Immune Globulin Therapy: An Overview, 805

Drug utilization, albumin, physician intervention (RPR) 239; antibiotics, Spain (IR) 662; ceftriaxone (L) 872; estrogens (PEP) 418; histamine$_2$-receptor antagonists (L) 681; human immunodeficiency virus (PEP) 1374; imipenem/cilastatin (L) 1399; ketorolac, formulary restriction (L) 1399; neuroleptic agents, Italy (PEP) 296; nicotine gum (RPR) 730

Drug withdrawal, beta-blockers (DIAS) 31

Drugs, availability, nifedipine, sustained-release (L) 317

Drugs, adverse reactions, acetylcholine, intraocular, hypotension, bradycardia (CR) 1178; altretamine, review (FF) 150; amantadine, neurotoxicity, renal transplant (CR) 1175; amphotericin B, hepatotoxicity (L) 559; aztreonam, myelosuppression (CR) 594; Bacillus Calmette-Guerin, review (A) 1361; bezafibrate, rhabdomyolysis (L) 869; capsaicin, review (FF) 385; ceftazidime, thrombocytopenia (SR) 135; ceftriaxone, thrombocytopenia (SR) 135; chlormezanone, fixed drug eruption (SR) 604; cilastatin, with imipenem, seizures (CR) 351; clofazimine, review (FF) 529; clonazepam, mania (SR) 938; database comparison (RPR) 1062; E5 monoclonal antibody, review (FF) 788; enalapril, agranulocytosis (CR) 461, psychosis (L) 558; erythromycin, agranulocytosis (L) 1136; extended-release tablets, gastric obstruction (L) 678; famotidine, arrhythmia (L) 315, thrombocytopenia (L) 678; felodipine, review (FF) 1202; fluorouracil, local tissue reaction (SR) 249; fluoxetine, glaucoma (L) 436, mania (L) 1395, review (DIR) 657, suicidal ideation (DIAS) 607; flurbiprofen, renal papillary necrosis (L) 870; flutamide, methemoglobinemia (SR) 600; foscarnet sodium, review (FF) 44; goserelin acetate, review (FF) 800; hepatitis B vaccines, review (A) 624, (A) 631; human monoclonal antibody, review (FF) 781; imipenem, with cilastatin, seizures (CR) 351; immune globulin, review (DSP) 812; interferon alfa-2a, impotence (L) 1397; ipratropium bromide, urinary retention (SR) 939; isoniazid, peripheral neuropathy (L) 100; ketoconazole, hepatotoxicity (CR) 1321, review (A) 397; leucovorin, local tissue reaction (SR) 249; lisinopril, hyponatremia (L) 873; literature search, manual vs. computer (L) 875; lithium, leukemia (TC) 948; lorazepam, maternal, neonatal feeding difficulties, muscle tone disorders (L) 1137; meperidine, taste alteration (L) 1137; mesalamine, review (FF) 143; mesna, hypertension (L) 867; methyldopa, granulomatous hepatitis (L) 1269; metoclopramide, urinary retention (SR) 469; mexiletine, pulmonary fibrosis (SR) 1329; misoprostol, delirium (SR) 133; molindone, neuroleptic malignant syndrome (SR) 1071; morphine, pruritus, cimetidine (RPR) 716; muromonab-CD3, aseptic meningitis (DIAS) 138, (L) 1395; naproxen, aseptic meningitis (SR) 1183; niacin, sustained-release, hepatotoxicity (L) 1014, review (DIAS) 253; nifedipine, hypertension (L) 99; nimodipine, bradycardia (CR) 247; ondansetron, review (FF) 377; pegademase bovine, review (FF) 1094; pentamidine, nephrotoxicity, hyperkalemia, AIDS (RPR) 1171; pentoxifylline, gastrointestinal bleeding (L) 315; phenothiazine, apnea (CR) 244; phenytoin, hypersensitivity (CR) 929; placebo, hypervagotonia (SR) 471; pravastatin, review (FF) 392; procainamide, myopathy (L) 436, pseudo-obstruction (SR) 1334; quinapril, review (FF) 502; rifampin, acute hemolysis, renal failure (SR) 743; roxithromycin, pancreatitis (L) 1137; sertraline, review (FF) 957; simvastatin, review (FF) 261; sympatholytic agents, review (DSP) 969; tetanus toxoid, anaphylaxis (L) 870; thiethylperazine, neuroleptic malignant syndrome (L) 1007; triazolam, market removal (E) 1263; trimethobenzamide, neuroleptic malignant syndrome (L) 1007; vancomycin, peritonitis (SR) 602, rash (CR) 1326; vitamin K$_1$, anaphylaxis (L) 871

Drugs, generic, product distrust (RC) 430

E

Economics, ciprofloxacin, oral, compared with parenteral antibiotics (PEP) 857

Edetate calcium disodium, lead intoxication (CR) 932

Editorials, see also, **An Opinion; Bosso, John A.,** Academic Pharmacy Practice and Research, 1129; **Gal, Peter, James, Cathe, Reed, Michael D.,** Indomethacin Therapy for Intraventricular Hemorrhage in Neonates: Another Use for that "Old" Drug, 1385; **Kelly, H. William,** Asthma, Aerosols, and Patient Education, 668; **Nahata, Milap C.,** Research Productivity and Funding, 669; **Perry, Paul J., Smith, Daniel A.,** Triazolam—The Never-Ending Story, 1263; **Usala, Anton-Lewis, Reed, Michael D.,** Clonidine Therapy for Short Stature: Can the Question be Put to Rest?, 1384; **Whitney, Harvey A.K., Jr.,** Reborn at Age 25, 97

Edrophonium chloride, myasthenia gravis (A) 1103

Education, continuing, medical vs. pharmaceutical (SR) 1336; pharmacy, B.S. vs. Pharm.D. degree (SC) 94, (L) 679, (L) 1400, Canadian Pharm.D. program (NC) 1158, changes in practice (O) 431, quality (RC) 1133, research, importance (E) 1129, Zimbabwe (IR) 302; physician, residencies, prescription writing (RPR) 17

Education and Research News (NC), Applications Invited for AIHP Grants, 1293; Campbell University Receives Maximum Accreditation, 1158; First Canadian Pharm.D. Program, 1158; First Chair in Geriatric Pharmacotherapy, 226; New Rho Chi–AFPE–Merck Scholarship, 1293

Educational Events, 6, 223, 332, 440, 561, 697, 881, 1030, 1154, 1289, 1418

Edwards, David J., Wayne State University Career Development Chair Award (NC) 1038

Electroconvulsive therapy, caffeine sodium benzoate (DIAS) 1079

EMBASE, compared with TOXLINE, MEDLINE, BIOSIS, IDIS, Core MEDLINE, PASCAL, PHARMALINE, IPA, adverse drug reactions (RPR) 1062

Emergency services, India (IR) 424

Emswiller, Carl F. Jr., president-elect, American College of Apothecaries (NC) 1431

Enalapril, agranulocytosis (CR) 461; compared with quinapril (FF) 501; congestive heart failure, review (A) 1351; psychosis (L) 558; vasodilatory stimulus, dynamic cerebral blood flow (RPR) 1299

Enalaprilat, intravenous, hypertension (SR) 25

Encainide, clearance, kidney failure (A) 1216; marketing discontinued (NC) 1294

Endocarditis, home care (A) 845; prophylaxis, erythromycin (L) 1396

Endomyometritis, postpartum, gentamicin pharmacokinetics (RPR) 1306

Endotoxin, human monoclonal antibody, review (FF) 778

Enoxacin, interaction, cations (DIR) 1250

Eosinophilia–myalgia syndrome, tryptophan, epidemiology (PEP) 1259

Ephedrine, hypertensive crisis (CR) 1068

Epinephrine, dosage, cardiopulmonary resuscitation (TC) 773; pediatric cardiopulmonary resuscitation (TC) 762

Epoxide hydrolase, phenytoin biotransformation (PED) 989

Equipment, finger oscillometric blood pressure device (RPR) 1310; heparin lock, necessity (A) 399; inhalers, metered-dose, drug delivery (PA) 638, patient education (E) 668; mechanical ventilators, home care (A) 843, parameters, nebulized drugs, neonates (PED) 272; Nordiject, human growth hormone (RPR) 585

Errors, medication, acetohexamide, acetazolamide mix-up (L) 100, France (PEP) 1113; prescribing, prevention (O) 1388

Erythromycin, agranulocytosis (L) 1136; clearance, kidney failure (A) 1217; interaction, cyclosporine (DIAS) 30, felodipine (L) 1007; postantibiotic effect (A) 154; prophylaxis, endocarditis (L) 1396

Esmolol, intravenous, acute aortic dissection (CR) 735; pharmacokinetics (DSP) 965; pharmacology (DSP) 962

Estrogens, drug utilization (PEP) 418
Ethics, marketing (L) 1138
Europe, AIDS, incidence (NC) 114
Excretion, carbamazepine, children (PED) 1109; glomerular filtration rate, index (CC) 169; hepatic, effect of kidney failure (A) 1214; hydroxychloroquine, rheumatoid arthritis (RPR) 1302; theophylline, cystic fibrosis (L) 212

F

Famotidine, arrhythmia (L) 315; thrombocytopenia (L) 678
FDA News (NC), FDA Toll-Free Line for Health Professionals, 1293
Federation Internationale Pharmaceutique, see **Association News (NC)**
Felbamate, pharmacokinetics (A) 979; review (A) 980
Fellowships and Residencies, California, University of California, San Francisco, 1418, University of Southern California, 1285; **Connecticut,** Hartford Hospital, 1417; **Idaho,** Idaho State University, 1417; **Maryland,** Center for Drug Evaluation and Research, Food and Drug Administration, 109, Maryland Poison Center, 333; **Michigan,** University of Michigan, 1285; **Missouri,** Marion Merrell Dow, 446, Quincy Research Center, 110, University of Missouri–Kansas City, 1417; **Nebraska,** St. Joseph Hospital, 1417; **New York,** Albany College of Pharmacy, 1417; **Texas,** University of Texas Health Science Center at San Antonio, 109; **Utah,** University of Utah, 1285
Felodipine, adverse reactions (FF) 1202; compared with amiloride (FF) 1198; compared with hydralazine (FF) 1199; compared with hydrochlorothiazide (FF) 1198; compared with metoprolol (FF) 1198; compared with nifedipine (FF) 1199; compared with prazosin (FF) 1199; compared with propranolol (FF) 1199; interaction, erythromycin (L) 1007; interactions, review (FF) 1202; pharmacokinetics (FF) 1195; pharmacology (FF) 1193; review (FF) 1193
Fentanyl, labeling (L) 1011
Fetal hydantoin syndrome, phenytoin biotransformation (PED) 987
Filtration, hemo, gentamicin, vancomycin removal (CR) 127
Finley, Rebecca S., board of directors, American Society of Hospital Pharmacists (NC) 1431
Flecainide, clearance, kidney failure (A) 1219
Fluconazole, compared with clotrimazole, vulvovaginal candidiasis (RPR) 582
Fludarabine, pharmacokinetics (FF) 519; review (FF) 518; toxicity (FF) 522
Fluoroquinolones, see **Quinolones**
Fluorouracil, local tissue reaction (SR) 249
Fluoxetine, adverse reactions, review (DIR) 657; bulimia (DIAS) 254; glaucoma (L) 436; interaction, imipramine (L) 1273; interactions, review (DIR) 657; mania (L) 1395; suicidal ideation (DIAS) 607
Flupenthixol decanoate, cocaine abuse (A) 821
Flurbiprofen, renal papillary necrosis (L) 870
Flutamide, methemoglobinemia (SR) 600
Folic acid, neural tube defects (NC) 1158; phenytoin biotransformation (PED) 989
Formulary Forum, Altretamine, 146; Clofazimine: A Review of Its Use in Leprosy and *Mycobacterium avium* Complex Infection, 525; E5 Monoclonal Immunoglobulin M Antibody for the Treatment of Gram-Negative Sepsis, 784; Felodipine: A New Dihydropyridine Calcium-Channel Antagonist, 1193; Fludarabine: A Review, 518; Foscarnet Sodium, 41; Goserelin Acetate Implant: A Depot Luteinizing Hormone-Releasing Hormone Analog for Advanced Prostate Cancer, 796; Human Monoclonal Antibody Against Endotoxin, 778; Idarubicin: A Second-Generation Anthracycline, 505; Intravenous Dipyridamole: Use in Thallous Chloride Tl 201 Stress Imaging, 1085; Mesalamine in Ulcerative Colitis, 140; Ondansetron: A Serotonin Receptor (5-HT3) Antagonist for Antineoplastic Chemotherapy-Induced Nausea and Vomiting, 367; Pegademase Bovine: Replacement Therapy for Severe Combined Immunodeficiency Disease, 1092; Pravastatin Sodium, a New HMG-CoA Reductase Inhibitor, 388; Quinapril: A New Second-Generation ACE Inhibitor, 499; Selegiline: Initial or Adjunctive Therapy of Parkinson's Disease, 36; Sertraline: A New Specific Serotonin Reuptake Blocker, 952; Simvastatin: A Review of Its Pharmacology and Clinical Use, 257; Topical Capsaicin in Dermatologic and Peripheral Pain Disorders, 381
Foscarnet sodium, adverse reactions, review (FF) 44; compared with acyclovir (FF) 43; pharmacokinetics (FF) 42; pharmacology (FF) 42; review (FF) 41
France, medication errors (PEP) 1113
Francke, Donald E., biographical sketch (SC) 425

G

Gabapentin, pharmacokinetics (A) 979; review (A) 982
Gamma hydroxy butyrate, illicit use, toxicity (NC) 114
Gastric obstruction, extended-release tablets (L) 678
Gemfibrozil, compared with simvastatin (FF) 260
General News (NC), Canthaxanthin: *DICP* Valuable in Aplastic Anemia Case, 701; *DICP* Appoints Two Editors, 1037; *Model Standards (3rd Ed)* Now Available, 1431; Pancreatic Enzyme Products, 1157; Use of Encainide and Moricizine Halted, 1294
Gentamicin, pharmacokinetics, postpartum endomyometritis (RPR) 1306; postantibiotic effect (A) 156; removal, hemofiltration (CR) 127
Geriatrics, ceftazidime, dosing schedule (G) 284; digoxin concentrations, Lanoxin vs. Lanoxicaps (RPR) 1043; drug information (G) 410; haloperidol, geriatric chair, brachial plexus palsy (SR) 1072; prescribing patterns, ambulatory care (G) 186; tuberculosis, review (G) 650
Geriatrics and Gerontology, Ceftazidime in the Elderly: Appropriateness of Twice-Daily Dosing, 284; Perceived Purpose of Prescription Drugs: The Iowa 65+ Rural Health Study, 410; Prescribing Patterns for Older Heavy Drug Users Living in the Community, 186; Tuberculosis in the Elderly: Incidence, Manifestations, PPD Skin Tests, and Preventive Therapy, 650
Glaucoma, fluoxetine (L) 436
Globulin, immune, A, E, D, G, M, review (DSP) 805; adverse reactions, review (DSP) 812; compared with corticosteroids (DSP) 809; idiopathic thrombocytopenic purpura, review (DSP) 808; pharmacokinetics (DSP) 807
Glomerular filtration, index, critical care (CC) 169
Glucose, biochemical marker, nutrition support (A) 265
Glucose-6-phosphate dehydrogenase, deficiency, aspirin (SR) 1074
Glutathione-S-transferase, phenytoin biotransformation (PED) 988
Gold, asthma, review (PA) 999
Goserelin acetate, adverse reactions (FF) 800; compared with diethylstilbestrol (FF) 799; pharmacodynamics (FF) 797; pharmacokinetics (FF) 797; pharmacology (FF) 796; prostate cancer, review (FF) 796
Granulocyte-macrophage colony-stimulating factor, neutropenia (DIAS) 32
Graves, Nina M., Fellow, ACCP (NC) 1038
Green, Melvin W., obituary (NC) 1294
Growth, acceleration, clonidine (DIAS) 1339, (E) 1384
Growth hormone, human, Nordiject delivery system (RPR) 585

H

Haloperidol, geriatric chair, brachial plexus palsy (SR) 1072; oral to im depot conversion, formulation (L) 1270
Halothane, hepatitis, colchicine (L) 211
Hart, Linda L., USPC drug information development programs (NC) 450
Healthcare, home, monitoring infections (A) 840; practice, competence (O) 205
Heart disease, congenital, alprostadil, neonatal transport (PED) 408
Heart failure, congestive, management, review (A) 1349
Hemofiltration, see **Filtration, hemo**
Hemorrhage, neonatal intraventricular, indomethacin (TC) 1344, (E) 1385
Heparin, acute myocardial infarction (TC) 613; admixture, parenteral nutrition (CC) 279; neonatal thrombosis (PED) 853; therapy institution, deep vein thrombosis (L) 1397
Hepatitis, granulomatous, methyldopa (L) 1269; halothane, colchicine (L) 211
Hepatitis B, transmission prevention (NC) 1157
Hepatitis B vaccines, adverse reactions (A) 624, (A) 631; intradermal (A) 628; utilization (O) 671; yeast-derived, review (A) 617
Hepatotoxicity, amphotericin B (L) 559; ketoconazole (CR) 1321
Histamine$_2$-receptor antagonists, admixture, parenteral nutrition (CC) 280; dosage form, conversion (PEC) 80; utilization, cost (L) 681
Human immunodeficiency virus, cost vs. disease progression, outpatients (PEC) 414; counseling, testing services (NC) 1431; dextran, inhibition (DIAS) 606; drug utilization (PEP) 1374; isoniazid, peripheral neuropathy (L) 100; mortality (NC) 338; transmission prevention (NC) 1157
Hydralazine, compared with felodipine (FF) 1199; congestive heart failure, review (A) 1351
Hydrochloric acid, admixture, parenteral nutrition (CC) 280
Hydrochlorothiazide, compared with felodipine (FF) 1198
Hydrocortisone, asthma, review (PA) 73, (PA) 998; compared with betamethasone, dexamethasone, asthma (PA) 73
Hydroxychloroquine, pharmacokinetics, rheumatoid arthritis (RPR) 1302
3-Hydroxyquinidine, toxicity (L) 867
Hypercholesterolemia, simvastatin (FF) 257
Hyperkalemia, AIDS, pentamidine (RPR) 1171
Hyperphosphatemia, calcium carbonate (DIAS) 945; phosphate binders (DIAS) 942
Hypersensitivity, see **Allergy**
Hypertension, crisis, ephedrine (CR) 1068, oxymetazoline (CR) 1068, phenylephrine (CR) 1068; economic analyses (PEC) 289; enalaprilat, intravenous (SR) 25; felodipine, review (FF) 1196; finger oscillometric blood pressure device (RPR) 1310; mesna (L) 867; nifedipine (L) 99
Hyponatremia, lisinopril (L) 873
Hypotension, acetylcholine, intraocular (CR) 1178

I-K

Idarubicin, pharmacokinetics (FF) 506; pharmacology (FF) 506; review (FF) 505; toxicity (FF) 512
Imipenem, postantibiotic effect (A) 154; with cilastatin, drug usage evaluation (RPR) 348, (L) 1399; seizures (CR) 351
Imipramine, cocaine abuse (A) 819; compared with dextroamphetamine, attention deficit disorder with hyperactivity (DSP) 1207; interaction, fluoxetine (L) 1273
Immune system, review (DSP) 805
Immunoassay, digoxin, anomalies (SR) 739
Immunoglobulin, myasthenia gravis (A) 1106; synthesis, schizophyllan, *Staphylococcus aureus* (L) 101
Immunosuppressive agents, myasthenia gravis (A) 1105
Impotence, alprostadil (DIAS) 362; interferon alfa-2a (L) 1397
Incompatibility, amphotericin B, magnesium sulfate (RPR) 123; ondansetron, dexamethasone (L) 869
India, emergency services (IR) 424
Indomethacin, neonatal intraventricular hemorrhage (TC) 1344, (E) 1385; no interaction, phenylpropanolamine (RPR) 234
Industry, pharmaceutical, US, abroad (RC) 427
Infections, monitoring, outpatients (A) 840; mycobacterial, ciprofloxacin (RPR) 919; skin, soft-tissue, teicoplanin (RPR) 914
Inhalers, metered-dose, instructions (L) 321
Insulin, admixture, parenteral nutrition (CC) 280
Intensive care units, charge, reimbursement (CC) 1231
Interferon alfa-2a, impotence (L) 1397
Interleukin-2, cancer (DSP) 490; pharmacokinetics (DSP) 493; review (DSP) 490; toxicity (DSP) 494
International normalized ratio, warfarin, interlaboratory effects (TC) 1190
International Pharmaceutical Abstracts, compared with EMBASE, TOXLINE, MEDLINE, BIOSIS, IDIS, Core MEDLINE, PASCAL, PHARMLINE, adverse drug reactions (RPR) 1062
International Reports, Attitude of the Public Toward Technical Package Inserts for Medication Information in Belgium, 1002; Comparative Study of Saudi-Marketed Products and US Drug Labeling, 863; Emergency Healthcare in India, 424; Prescribing Patterns in Saudi Arabia, 90; Recommendations for Establishing a Drug and Toxicology Information Center in a Developing Country, 1379; The Profession of Pharmacy in Zimbabwe, 302; Use of Restricted Antibiotics in Primary Care, 662
Intubation, children, ketamine/succinylcholine (DIAS) 475
Iowa, rural health study, drug information, elderly (G) 410
Iowa Drug Information Service, compared with EMBASE, TOXLINE, MEDLINE, BIOSIS, Core MEDLINE, PASCAL, PHARMLINE, IPA, adverse drug reactions (RPR) 1062
Ipratropium, asthma, review (PA) 998; bromide, urinary retention (SR) 939
Iron, interaction, quinolones (DIR) 1253
I-Scrub, blepharitis (SR) 359
Isoniazid, interaction, clofazimine, review (FF) 530; peripheral neuropathy (L) 100
Isosorbide dinitrate, dosing, tolerance (L) 1272
Isradipine, clearance, kidney failure (A) 1218
Italy, neuroleptic drug utilization (PEP) 296
Joint Commission of Pharmacy Practitioners, see **Association News (NC)**
Joint Commission on Accreditation of Healthcare Organizations, outcome criteria (O) 205
Kaul, Alan F., president, Health Outcomes Management, Ltd. (NC) 1431
Kelly, William N., board of directors, American Society of Hospital Pharmacists (NC) 1431
Ketamine, with succinylcholine, intubation, children (DIAS) 475
Ketoconazole, adverse effects (A) 397; hepatotoxicity (CR) 1321; pityriasis versicolor (A) 395; utilization (PEP) 1374
Ketorolac, utilization, formulary restriction (L) 1399
Kidney failure, AIDS, pentamidine (RPR) 1171; calcium carbonate (DIAS) 945; digoxin immune Fab, digoxin dissociation (L) 1269, pharmacokinetics (CR) 1315; glomerular filtration rate, index (CC) 169; hepatic drug clearance (A) 1214; phosphate binders (DIAS) 942; rifampin (SR) 743
Knapp, David A., dean, School of Pharmacy, University of Maryland (NC) 906

L

Labeling, fentanyl (L) 1011
Labetalol, beta-adrenergic receptor response, racial groups (A) 827; hydrochloride, stability (SR) 465
Labor, prostaglandin E$_2$, gel compared with suppository (RPR) 456
Laboratories, interlaboratory effects, warfarin, international normalized ratio (TC) 1190

Lactate, biochemical marker, nutrition support (A) 265
Lake, Kathleen D., Albert B. Prescott/Glaxo Leadership Award, Phi Delta Chi (NC) 450
Lamotrigine, pharmacokinetics (A) 979; review (A) 983
Lamp, Kenneth, Merck Foundation Fellow in Infectious Diseases (NC) 1038
Lamy, Peter P., endowed chair in Geriatric Pharmacotherapy (NC) 226
Laws, Controlled Substances Act, cancer patients (A) 1229; litigation, review (SC) 195; patient counseling (L) 1274; psychotherapeutic agents, refusal (A) 849
Lead, toxicity (CR) 932
Letters, Accidental Intravenous Infusion of Sodium Hypochlorite, 1008; Accumulation of 3-Hydroxyquinidine Following Chronic Quinidine Therapy, 867; Acute Pancreatitis Associated with Roxithromycin Therapy, 1137; Adverse Effects of Maternal Lorazepam on Neonates, 1137; Adverse Reactions to Phenothiazine Antiemetics in AIDS, 1007; Aminoglycosides: Determination of New Therapeutic Ranges, 558; Aseptic Meningitis Associated with Muromonab-CD3, 1395; Bezafibrate-Induced Rhabdomyolysis, 869; Ceftriaxone Drug Utilization Evaluation in a Large Community Hospital, 872; Ciprofloxacin–Warfarin Interaction, 1397; Colchicine to Prevent Halothane Hepatitis?, 211; Computer Monitoring Ciprofloxacin–Theophylline Interactions, 1011; Confusing Bacterial Endocarditis Recommendations, 1396; Cost Considerations of Conversion from Aminoglycoside-Containing Combination Regimens to Ceftriaxone, 319; Digoxin—Farewell, Old Friend or Un-Squill We Meet Again!, 320; Drug Company Influence, 1138; Drug-Induced Systemic Lupus Erythematosus, 212; Duragesic Package Labeling, 1011; Early Anticoagulation Therapy in Deep Vein Thrombosis, 1397; Effect of a Light Breakfast on the Bioavailability of Sustained-Release Nifedipine, 317; Effect of Coadministration of Acyclovir and Cyclosporine on Kidney Function and Cyclosporine Concentrations in Renal Transplant Patients, 316; Effect of Plasmapheresis on Cyclosporine, 211; Enalapril-Induced Acute Psychosis, 558; Erythromycin–Felodipine Interaction, 1007; Erythromycin-Induced Agranulocytosis, 1136; Eternal Significance, 215; Evaluation of Concomitant Drug Use During Antidepressant Therapy, 213; Evaluation of Generic–Brand Name Knowledge, 1138; Famotidine and Cardiac Arrhythmia, 315; Fluoxetine and Glaucoma, 436; Fluoxetine-Induced Mania in a Suicidal Depressed Patient, 1395; Gastric Obstruction with Extended-Release Tablets, 678; Hepatocellular Carcinoma Response to Low-Dose Oral Tegafur, 1009; Hypersensitivity to Clindamycin, 317; Imipenem/Cilastatin Drug Utilization Evaluation in a Large Community Hospital, 1399; Inadvertent Administration of Acetohexamide Instead of Acetazolamide, 100; Inadvertent Intravenous Administration of Methylprednisolone Acetate in a Child, 436; Interaction of Phenothiazine and Related Drugs and Caffeinated Beverages, 437; Ketorolac Formulary Restriction and Usage Evaluation, 1399; Lisinopril-Induced Lithium Toxicity, 101; Manual or Computer-Based Literature Searches: Is One Best for Pharmacovigilance?, 214; Meperidine-Induced Taste Alteration, 1137; Mesna Therapy and Hypertension, 867; Methyldopa-Induced Granulomatous Hepatitis, 1269; Neonatal Fever and Cyanotic Spells from Maternal Chlorpromazine, 1009; Nitrate Tolerance: Does TID Isosorbide Dinitrate Mean Dosing Every Eight Hours?, 1272; Pentoxifylline-Induced Gastrointestinal Bleeding, 315; Peripheral Neuropathy in HIV Patient After Isoniazid, 100; Pharmacist Involvement in Society of Critical Care Medicine, 1398; Phenytoin–Tizanidine Interaction, 1273; Possible Dissociation of the Digibind–Digoxin Complex in Renal Failure, 1269; Possible Procainamide-Induced Myopathy, 436; Preliminary Clinical Evidence for Analgesic Effect of Vapreotide, 1136; Probable Famotidine-Induced Thrombocytopenia, 678; *Pseudomonas aeruginosa* Resistance to Ceftazidime, 871; Relationship Between Tranylcypromine Sulfate Dose and Monoamine Oxidase Inhibition, 99; Renal Papillary Necrosis Induced by Flurbiprofen, 870; Schizophyllan Augments Development of Immunoglobulin-Secreting Cells upon Costimulation with *Staphylococcus aureus* Cowan I, 101; Sources of Influence on the Prescribing Practices of Residents in Family Medicine, 102; Streptokinase Versus Recombinant Tissue-Type Plasminogen Activator, 1271; Subtherapeutic Serum Drug Concentrations and Compliance, 103; Switching Haloperidol from Oral to IM Depot Formulation, 1270; Tetanus Toxoid Anaphylaxis, 870; Unresponsiveness to Nifedipine Treatment, 99; Variable Theophylline Clearance in Cystic Fibrosis, 212; Vertigo Caused by Intravenous Imipenem/Cilastatin, 1009; Visual compatibility of Ondansetron and Dexamethasone, 869; Vitamin K_1 and Anaphylactic Shock, 871; Volmax: Simulated Gastrointestinal pH and Agitation Studies, 438; We Use Drugs Too—More Pediatric Information in Review Articles, 559
  Comments/Author Replies, Adverse-Effect Profile of Sustained-Release Niacin, 1014, Aminoglycoside Dosing, 1141, Attribution of Blame in Drug-Induced Thrombocytopenia, 874, Consideration of Amphotericin B Hepatotoxicity, 559, Fluoxetine Adverse Effects and Drug Interactions, 1273, Legal Duty to Counsel, 1274, Lisinopril-Induced Hyponatremia, 873, Manual Versus Computer-Based Literature Searches for Adverse Drug Reactions, 875, Mesalamine in Ulcerative Colitis, 1015, Metered-Dose Inhalers, 321, Origins of Clinical Pharmacy, 1142, Parenteral H_2-Receptor Antagonist Intervention, 681, Pharm.D.: All or Some?, 679, 1400, Plicamycin Infusion, 215, Potassium Supplements vs. Potassium-Sparing Diuretics, 439, Ranitidine Does Not Inhibit Theophylline Metabolism, 1139, Subtherapeutic Drug Concentrations and Compliance, 1016
  Corrections, Clonidine Patch Toxicity, 682, Dipyridamole in Angioplasty, 1274, Figures Transposed, 1017, Mechanical Ventilation, 1017, References Misnumbered, 876
Leucovorin, local tissue reaction (SR) 249
Leukemia, immune globulin, review (DSP) 811; lithium (TC) 948
Lidocaine, absorption, age (SR) 463; clearance, kidney failure (A) 1218; pediatric cardiopulmonary resuscitation (TC) 768
Lisinopril, hyponatremia (L) 873; interaction, lithium (L) 101
Literature, manual vs. computer-based searches (L) 214, (L) 875
Lithium, cocaine abuse (A) 821; interaction, lisinopril (L) 101; leukemia (TC) 948
Lopez, Larry M., Fellow, ACCP (NC) 1038
Lorazepam, maternal, neonatal feeding difficulties, muscle tone disorders (L) 1137
Lymphomas, home care (A) 847

M

Magnesium sulfate, compatibility, amphotericin B (RPR) 123
Mania, clonazepam (SR) 938; fluoxetine (L) 1395
Maprotiline, cocaine abuse (A) 819
Marketing, encainide removal (NC) 1294; ethics (L) 1138; triazolam removal (E) 1263
Massachusetts, women, estrogen use (PEP) 418
Mathematics, pharmacokinetics, bacterial susceptibility, cefmenoxime, ciprofloxacin, tobramycin (RPR) 1050
McGhan, William F., executive director, Institute for Pharmaceutical Economics (NC) 906; USPC drug information development programs (NC) 450
Measles, vaccination levels (NC) 338
MEDLINE, compared with EMBASE, TOXLINE, BIOSIS, IDIS, Core MEDLINE, PASCAL, PHARMLINE, IPA, adverse drug reactions (RPR) 1062
Mefloquine, dosing regimen changed (NC) 450
Meningitis, aseptic, muromonab-CD3 (DIAS) 138, (L) 1395, naproxen (SR) 1183; **bacterial,** corticosteroids, infants, children (PED) 542; neonates, ceftriaxone (SR) 27
Meperidine, concentrations, postoperative (RPR) 724; taste alteration (L) 1137
Mercaptopurine, myasthenia gravis (A) 1105
Mesalamine, adverse reactions (FF) 143; compared with corticosteroid enemas (FF) 142; compared with sulfasalazine (FF) 142; pharmacokinetics (FF) 141; review (FF) 140; ulcerative colitis (L) 1015
Mesna, hypertension (L) 867
Metabolism, theophylline, ranitidine inhibition (L) 1139
Methicillin, postantibiotic effect (A) 155
Methixene, compared with selegiline, Parkinson's disease (FF) 39
Methotrexate, asthma, review (PA) 999; myasthenia gravis (A) 1105
Methyldopa, granulomatous hepatitis (L) 1269
3-Methylhistidine, biochemical marker, nutrition support (A) 265
Methylphenidate, attention deficit disorder with hyperactivity (DSP) 1208; hydrochloride, cocaine abuse (A) 820
Methylprednisolone, acetate, intravenous administration (L) 436; asthma (PA) 73; myasthenia gravis (A) 1105
Metoclopramide, clearance, kidney failure (A) 1215; compared with ondansetron (FF) 373; urinary retention (SR) 469
Metoprolol, clearance, kidney failure (A) 1218; compared with felodipine (FF) 1198; pharmacokinetics (DSP) 965; pharmacology (DSP) 962
Mexiletine, interaction, theophylline (RPR) 727; pulmonary fibrosis (SR) 1329
Midazolam, administration routes (DIAS) 476
Migraine, prophylaxis, calcitonin (DIAS) 1185, verapamil (DIAS) 1076
Milrinone, congestive heart failure, review (A) 1352
Misoprostol, delirium (SR) 133
Mitomycin, superficial bladder cancer (A) 1357
Molindone, neuroleptic malignant syndrome (SR) 1071
Moncamine oxidase inhibition, tranylcypromine sulfate, dose (L) 99
Monoamine oxidase inhibitors, cocaine abuse (A) 820
Monobactams, with beta-lactams, synergy (A) 974
Mood disorder, lithium, leukemia (TC) 948
Moricizine, use in study halted (NC) 1294
Morphine, epidural, pruritus, cimetidine (RPR) 716; utilization (PEP) 1374
Moxalactam, postantibiotic effect (A) 156
Mupirocin, methicillin-resistant *Staphyolococcus aureus* vaginitis (SR) 1331
Muromonab-CD3, aseptic meningitis (DIAS) 138, (L) 1395
Myasthenia gravis, cholinesterase inhibitors (A) 1103; corticosteroids (A) 1104; cyclosporine (A) 1106; immunoglobulin (A) 1106; immunosuppressive agents (A) 1105; neostigmine bromide (A) 1103; review (A) 1101
Myocardial infarction, acute, heparin (TC) 613; thrombolytics, administration delay (A) 1096
Myopathy, procainamide (L) 436

N

Nadolol, pharmacokinetics (DSP) 965
Nafarelin, figure credit (L) 321
Nafcillin, interaction, warfarin (CR) 598; postantibiotic effect (A) 155
Nahata, Milap C., 1991 Distinguished Teaching Award, Ohio State University (NC) 572
Nalidixic acid, interaction, cations (DIR) 1250
Naloxone, pediatric cardiopulmonary resuscitation (TC) 768
Naproxen, aseptic meningitis (SR) 1183
National Association of Chain Drug Stores, see **Association News (NC)**
Necrosis, renal papillary, flurbiprofen (L) 870
Neostigmine bromide, myasthenia gravis (A) 1103
Netilmicin, postantibiotic effect (A) 156
Neuralgia, postherpetic, topical aspirin (DIAS) 1077
Neuroleptic agents, see **Psychotherapeutic agents**
Neuroleptic malignant syndrome, molindone (SR) 1071; phenothiazine antiemetics (L) 1007
Neurotoxicity, amantadine, renal transplant (CR) 1175
Neutropenia, granulocyte-macrophage colony-stimulating factor (DIAS) 32
New Publications, see **Book Reviews, Books Received**
News and Comments, 114, 226, 338, 450, 572, 701, 905, 1037, 1157, 1293, 1430; see also, **Association News, Education and Research News, FDA News, General News, Obituary, USPHS–CDC News, USPHS News, VIP News**
Niacin, sustained-release, adverse reactions (DIAS) 253, hepatoxicity (L) 1014
Niacinamide, bullous pemphigoid (DIAS) 1187
Nicotine, gum, utilization (RPR) 730
Nifedipine, clearance, kidney failure (A) 1218; compared with felodipine (FF) 1199; hypertension (L) 99; sustained-release, bioavailability (L) 317
Nimodipine, bradycardia (CR) 247; clearance, kidney failure (A) 1216
Nisoldipine, clearance, kidney failure (A) 1218
Nitrendipine, clearance, kidney failure (A) 1218
Nitrogen, urinary, biochemical marker, nutrition support (A) 265
Nomenclature, generic–brand name knowledge, physicians, pharmacists (L) 1138
Nortriptyline, attention deficit disorder with hyperactivity (DSP) 1209; clearance, kidney failure (A) 1217; pharmacokinetics (TM) 1368
Nutrition, parenteral, drug vehicle, review (CC) 276, fluid balance, ICU patients (RPR) 119; support, biochemical markers (A) 265

O-P

Obituary (NC), Green, Melvin W., 1294
Obstetrics, gentamicin pharmacokinetics, postpartum endomyometritis (RPR) 1306
Obstruction, pseudo-, procainamide (SR) 1334
Ofloxacin, interaction, cations (DIR) 1250; pregnancy (SR) 1181
Ondansetron, adverse effects (FF) 377; compared with metoclopramide (FF) 373; compatibility, dexamethasone (L) 869; pharmacodynamics (FF) 369; pharmacokinetics (FF) 369; pharmacology (FF) 367; review (FF) 367
Ophthalmopathy, Graves', cyclosporine (DIAS) 750
Opinions, see **An Opinion; Editorials**
Osteomyelitis, home care (A) 844
Oxazepam, clearance, kidney failure (A) 1220
Oxygen, biochemical marker, nutrition support (A) 265
Oxymetazoline, hypertensive crisis (CR) 1068
Package inserts, Belgium (IR) 1002; NSAIDs, Saudi Arabia compared with US (IR) 863
Pain, cancer, management (A) 1225; patient-controlled analgesia (RPR) 1058
Pancreatic enzymes, prescription only, cystic fibrosis (NC) 1157
Pancreatitis, roxithromycin (L) 1137
Pancuronium, pharmacodynamics (A) 58; pharmacokinetics (A) 58
Parkinson's disease, selegiline, review (FF) 36; tricyclic antidepressants (DIAS) 137
PASCAL, compared with EMBASE, TOXLINE, MEDLINE, BIOSIS, IDIS, Core MEDLINE, PHARMLINE, IPA, adverse drug reactions (RPR) 1062
Patient-controlled analgesia, evaluation (RPR) 1058
Patient education, asthma (E) 668; clinical pharmacy (A) 164; laws (L) 1274; metered-dose inhalers (PA) 641
Patient information, litigation, review (SC) 195
Patients, outpatients, monitoring infections (A) 840
Pediatrics, activated charcoal, pharmacokinetics, phenytoin poisoning (PED) 646; alprostadil, congenital heart disease, neonatal transport (PED) 408; carbamazepine, therapeutic monitoring (PED) 1109; cardiopulmonary resuscitation, infants, children (TC) 760; ceftizoxime, neonates, infants (RPR) 344; cefuroxime axetil, suspension (PED) 1236; clonidine, growth acceleration (DIAS) 1339; corticosteroids, meningitis

(PED) 542; diphenhydramine toxicity, varicella zoster (CR) 130; indomethacin, intraventricular hemorrhage, neonates (TC) 1344, (E) 1385; information, review articles (L) 559; ketamine/succinylcholine, intubation (DIAS) 475; lorazepam, maternal, feeding difficulties, muscle tone disorders (L) 1137; medication errors, France (PEP) 1113; neonates, ceftriaxone, *Citrobacter freundii* meningitis (SR) 27, ventilator parameters (PED) 272; phenytoin, teratogenicity (PED) 987; procainamide, neonates (PED) 68; theophylline, dosage (PED) 179; thrombosis, heparin (PED) 853

Pediatrics (PED), Carbamazepine Dosing for Pediatric Seizure Disorders: The Highs and Lows, 1109; Differences in Phenytoin Biotransformation and Susceptibility to Congenital Malformations: A Review, 987; Evaluation of Three Theophylline Dosing Methods in Pediatric Patients, 179; Neonatal Thrombosis: Treatment with Heparin and Thrombolytics, 853; Pharmacokinetic Simulation of the Effect of Multiple-Dose Activated Charcoal in Phenytoin Poisoning—Report of Two Pediatric Cases, 646; Prostaglandin E_1 Treatment of Congenital Heart Disease: Use Prior to Neonatal Transport, 408; The Impact of Changing Ventilator Parameters on Availability of Nebulized Drugs in an In Vitro Neonatal Lung System, 272; The Role of Corticosteroids in Infants and Children with Bacterial Meningitis, 542; The Safety, Efficacy, and Tolerability of Cefuroxime Axetil Suspension in Infants and Children Receiving Previous Intravenous Antibiotic Therapy, 1236; Therapeutic Monitoring and Pharmacokinetic Evaluation of Procainamide in Neonates, 68

Pegademase bovine, adverse reactions (FF) 1094; interaction, pentostatin, vidarabine, review (FF) 1094; pharmacokinetics (FF) 1094; review (FF) 1092

Pemphigoid, bullous, niacinamide (DIAS) 1187

Penbutolol, pharmacokinetics (DSP) 965; pharmacology (DSP) 963

Penicillin G, postantibiotic effect (A) 155

Penicillins, drug information, outpatients (RPR) 925; postantibiotic effect (A) 154

Pentamidine, nephrotoxicity, hyperkalemia, AIDS (RPR) 1171; utilization (PEP) 1374

Pentostatin, interaction, pegademase bovine, review (FF) 1094

Pentoxifylline, gastrointestinal bleeding (L) 315

Peritonitis, chemical, vancomycin (SR) 602

Personnel Placement, see separate section: **ADVERTISERS**

Pharmacodynamics, atracurium (A) 59; curare (A) 57; dipyridamole (FF) 1086; goserelin acetate (FF) 797; ondansetron (FF) 369; pancuronium (A) 58; pravastatin (FF) 389; succinylcholine (A) 57; vecuronium (A) 58

Pharmacoeconomics, analyses, hypertension (PEC) 289; conversion, aminoglycoside regimens to ceftriaxone (L) 319; cost, antibiotic dosing frequencies (PEC) 546, conversion from parenteral to oral H_2-receptor antagonists (PEC) 80, HIV patient drugs (PEC) 414; drug usage evaluation, imipenem/cilastatin (RPR) 348; intensive care units, charge, reimbursement (CC) 1231; ranitidine, conversion of iv to po (SR) 251

Pharmacoeconomics (PEC), Economic Analyses in Hypertension: Applications for Healthcare Providers, 289; Evaluating the Cost Impact of Intravenous Antibiotic Dosing Frequencies, 546; Evaluation of Direct Pharmacist Intervention on Conversion from Parenteral to Oral Histamine H_2-Receptor Antagonist Therapy, 80; The Relationship Between Outpatient Drug Costs and Disease Progression in the Human Immunodeficiency Virus-Infected Population, 414

Pharmacoepidemiology (PEP), Characteristics of Medication Errors in Pediatrics, 1113; Clinical and Economic Impact of Oral Ciprofloxacin as Follow-Up to Parenteral Antibiotics, 857; Medication Usage Patterns in Patients with Human Immunodeficiency Virus Infection: A Comparison of Patient Reported Medication Usage with Medical Chart Review, 1374; Pattern of Neuroleptic Drug Use in Italian Mental Health Services, 296; Psychotropic Medication Prescription in US Ambulatory Medical Care, 85; Tryptophan Toxicity: A Pharmacoepidemiologic Review of Eosinophilia–Myalgia Syndrome, 1259; Use of Estrogens Among Middle-Aged Massachusetts Women, 418

Pharmacokinetics, acetylcysteine absorption, activated charcoal (TC) 1081; actisomide (RPR) 231; activated charcoal, phenytoin poisoning (PED) 646; altretamine (FF) 147; aminoglycosides, two- vs. three-point method (TM) 635; amitriptyline (TM) 1368; atracurium (A) 59; capsaicin (FF) 383; cefmenoxime, bacterial susceptibility (RPR) 1050; ceftazidime, elderly (G) 285; ceftizoxime, neonates, infants (RPR) 344; ciprofloxacin, bacterial susceptibility (RPR) 1050; clofazimine (FF) 526; colony-stimulating factors (DSP) 491; curare (A) 58; cyclosporine, plasmapheresis (L) 211; desipramine (TM) 1368; digoxin immune Fab, kidney failure (CR) 1315; dipyridamole (FF) 1086; doxepin (TM) 1368; E5 monoclonal antibody (FF) 787; felbamate (A) 979; felodipine (FF) 1195; fludarabine (FF) 519; foscarnet sodium (FF) 42; gabapentin (A) 979; gentamicin, endomyometritis (RPR) 1306; goserelin acetate (FF) 797; human monoclonal antibody (FF) 780; hydroxychloroquine, rheumatoid arthritis (RPR) 1302; idarubicin (FF) 506; imipramine (TM) 1368; immune globulin (DSP) 807; interleukin-2 (DSP) 493; lamotrigine (A) 979; mesalamine (FF) 141; nortriptyline (TM) 1368; ondansetron (FF) 369; pancuronium (A) 58; pegademase bovine (FF) 1094; pravastatin (FF) 389; procainamide, neonates (PED) 68; quinapril (FF) 500; sertraline (FF) 953; simvastatin (FF) 258; succinylcholine (A) 57; sympatholytic agents (DSP) 964; tobramycin, bacterial susceptibility (RPR) 1050; tricyclic antidepressants (TM) 1368; vecuronium (A) 59; vigabatrin (A) 979

Pharmacology, altretamine (FF) 147; capsaicin (FF) 382; clofazimine (FF) 525; felodipine (FF) 1193; foscarnet sodium (FF) 42; goserelin acetate (FF) 796; idarubicin (FF) 506; neuromuscular blocking agents (A) 54; pravastatin (FF) 388; quinapril (FF) 499; sertraline (FF) 952; sympatholytic agents (DSP) 962

Pharmacotherapy, see also, **Pharmacy, clinical;** changes in practice (O) 431; patient outcomes (O) 208; prescribing errors, prevention (O) 1388; professional interaction, physicians (O) 1132; research (E) 1129; Society of Critical Care Medicine, pharmacist involvement (L) 1398

Pharmacotherapy Case Reports, Agranulocytosis Associated with Enalapril, 461; Amantadine Neurotoxicity in a Pediatric Patient with Renal Insufficiency, 1175; Aztreonam-Induced Myelosuppression During Treatment of *Pseudomonas aeruginosa* Pneumonia, 594; Clinical and Pharmacokinetic Profiles of Digoxin Immune Fab in Four Patients with Renal Impairment, 1315; Decreased Hypoprothrombinemic Response to Warfarin Secondary to the Warfarin–Nafcillin Interaction, 598; Diphenhydramine Toxicity in Three Children with Varicella-Zoster Infection, 130; Gentamicin and Vancomycin Removal by Continuous Venovenous Hemofiltration, 127; Hypertensive Crisis from Chronic Intoxication with Nasal Decongestant and Cough Medications, 1068; Hypotension and Bradycardia Possibly Associated with Intraocular Injection of Acetylcholine, 1178; Impaired Water Homeostasis Following Mixed Carbamazepine and Phenobarbital Overdose, 354; Intravenous Esmolol in Acute Aortic Dissection, 735; Ketoconazole Hepatotoxicity in a Patient Treated for Environmental Illness and Systemic Candidiasis, 1321; Nimodipine and Bradycardia in Acute Stroke—Drug or Disease?, 247; Oral Vancomycin-Induced Rash: Case Report and Review of the Literature, 1326; Phenothiazine-Associated Apnea in Two Siblings, 244; Phenytoin Hypersensitivity Syndrome: A Case Report, 929; Ranitidine–Theophylline Interaction—Fact or Fiction?, 21; Seizure Activity Associated with Imipenem Use: Clinical Case Reports and Review of the Literature, 351; Suspected Central Nervous System Toxicity from Inadvertent Nonsteroidal Antiinflammatory Drug Overdose, 1066; Ten Cases of Acute Lead Intoxication Among Bridge Workers in Louisiana, 932

Pharmacy, clinical, see also, **Pharmacotherapy**; dosage form conversion (PEC) 80; education, B.S. vs. Pharm.D. (SC) 94, (L) 679, (L) 1400; clinical, medical vs pharmaceutical (SR) 1336; education/ practice, Zimbabwe (IR) 302; ICU patients, fluid balance (RPR) 119; origins (L) 1142; patient information, litigation (SC) 195; patient intervention (A) 164; quality (RC) 1133; University of California, San Francisco (SC) 308

PHARMLINE, compared with EMBASE, TOXLINE, MEDLINE, BIOSIS, IDIS, Core MEDLINE, PASCAL, IPA, adverse drug reactions (RPR) 1062

Phenobarbital, with carbamazepine, acute water intoxication (CR) 354

Phenothiazine, apnea (CR) 244; interaction, caffeine (L) 437

Phenylephrine, hypertensive crisis (CR) 1068

Phenylpropanolamine, no interaction, indomethacin (RPR) 234

Phenytoin, concentrations, compliance (L) 103; hypersensitivity (CR) 929; interaction, tizanidine (L) 1273; toxicity, activated charcoal, pharmacokinetics (PED) 646

Phosphate binders, kidney failure (DIAS) 942

Physicians, intervention, albumin utilization (RPR) 239; pharmacist interaction (O) 1132; prescribing errors, prevention (O) 1388; prescribing practices, drug information sources (L) 102; residencies, prescription writing (RPR) 17

Pindolol, beta-adrenergic receptor response, racial groups (A) 826; pharmacokinetics (DSP) 965; pharmacology (DSP) 963

Piperacillin, interaction, tobramycin (SR) 357; postantibiotic effect (A) 155

Pityriasis versicolor, ketoconazole (A) 395

Placebo, hypervagotonia (SR) 471

Plasmapheresis, cyclosporine, pharmacokinetics (L) 211

Platelets, adverse drug reactions (L) 874

Pleural effusion, malignant, talc (DIAS) 1187

Plicamycin, dosage schedule (L) 215

Pneumocystis carinii, pneumonia, trimethoprim/sulfamethoxazole (DIAS) 941

Pneumonia, *Pneumocystis carinii*, trimethoprim/sulfamethoxazole (DIAS) 941; *Pseudomonas aeruginosa*, aztreonam (CR) 594

Ponte, Charles D., USPC panel of experts, family practice (NC) 572

Potassium, supplements vs. potassium-sparing diuretics (L) 439

Pravastatin, adverse reactions (FF) 392; interactions, review (FF) 392; pharmacodynamics (FF) 389; pharmacokinetics (FF) 389; pharmacology (FF) 388; review (FF) 388

Prazosin, compared with felodipine (FF) 1199; vasodilatory stimulus, dynamic cerebral blood flow (RPR) 1299

Prednisone, asthma (PA) 73; myasthenia gravis (A) 1105

Pregnancy, ofloxacin (SR) 1181

Premenstrual syndrome, verapamil (DIAS) 361

Prescribing, family medicine residents, drug information sources (L) 102; patterns, geriatrics (G) 186; skills, residents (RPR) 17

Prescriptions, ambulatory care, Saudi Arabia (IR) 90; psychotherapeutic agents, ambulatory care (PEP) 85

Probucol, compared with simvastatin (FF) 260

Procainamide, myopathy (L) 436; pseudo-obstruction (SR) 1334

Professional competence, determinants (O) 205; patient outcomes (O) 208

Propafenone, clearance, kidney failure (A) 1220

Prophylaxis, antibiotic, coronary bypass surgery (TC) 478; endocarditis, erythromycin (L) 1396; migraine, calcitonin (DIAS) 1185, verapamil (DIAS) 1076; neonatal intraventricular hemorrhage, indomethacin (TC) 1344, (E) 1385; surgical, cefotetan compared with cefoxitin (RPR) 10

Propoxyphene, clearance, kidney failure (A) 1217

Propranolol, beta-adrenergic receptor response, racial groups (A) 825; clearance, kidney failure (A) 1215; compared with chlordiazepoxide, alcohol withdrawal (DIAS) 32; compared with felodipine (FF) 1199; pharmacokinetics (DSP) 965; pharmacology (DSP) 963

Prostaglandin E_1, see **Alprostadil**

Prostaglandin E_2, gel compared with suppository, cervical ripening (RPR) 456

Protein, acute phase, biochemical marker, nutrition support (A) 265; visceral, biochemical marker, nutrition support (A) 265

Pseudomonas aeruginosa, resistance, ceftazidime (L) 871

Psoriasis, vitamin D (DIAS) 753, review (A) 835

Psychosis, enalapril (L) 558

Psychotherapeutic agents, antidepressants, concomitant drug use (L) 213; neuroleptics, drug utilization, Italian mental health services (PEP) 296; prescriptions, ambulatory care (PEP) 85; refusal, laws (A) 849; tricyclic antidepressants, Parkinson's disease (DIAS) 137

Pulmonary and Allergy, Corticosteroids for Acute, Severe Asthma, 72; Optimizing Drug Delivery from Metered-Dose Inhalers, 638; Pathogenesis of Asthma: Therapeutic Implications, 993

Pulmonary fibrosis, mexiletine (SR) 1329

Pyridostigmine bromide, myasthenia gravis (A) 1103

Pyruvate, biochemical marker, nutrition support (A) 266

Q-R

Quinapril, adverse reactions (FF) 502; compared with captopril (FF) 500; compared with enalapril (FF) 501; interactions (FF) 502; pharmacokinetics (FF) 500; pharmacology (FF) 499; review (FF) 499

Quinidine, gluconate, *Plasmodium falciparum* (NC) 906; 3-hydroxyquinidine toxicity (L) 867; with digoxin/warfarin, interaction, sucralfate (SR) 745

Quinine, parenteral, discontinuation (NC) 906

Quinolones, interaction, cations (DIR) 1249, theophylline, meta-analysis (DIR) 191; postantibiotic effect (A) 154

Race, beta-adrenergic receptor response, differences (A) 824

Ranitidine, conversion of iv to po (SR) 251; interaction, theophylline (CR) 21; theophylline metabolism inhibition (L) 1139

Rash, vancomycin (CR) 1326

Release, Volmax (L) 438

Research, academic pharmacy practice (E) 1129; funding, productivity (E) 669

Research/Practice Reports, A Comparative Evaluation of the Safety and Efficacy of Cefotetan and Cefoxitin in Surgical Prophylaxis, 10; Assessing the Effects of Antihypertensive Medication on Cerebral Blood Flow: Demonstration in Internal Carotid Artery Occlusion, 1299; Ceftizoxime Disposition in Neonates and Infants During the First Six Months of Life, 344; Ciprofloxacin in Patients with Mycobacterial Infections: Experience in 15 Patients, 919; Clinical Evaluation of a Finger Oscillometric Blood Pressure Device, 1310; Combined Use of Ciprofloxacin and Sucralfate, 578; Comparative Attitudes to Verbal and Written Medication Information Among Hospital Outpatients, 925; Comparative Efficacy of Intravaginal Prostaglandin E_2 in the Gel and Suppository Forms for Cervical Ripening, 456; Comparative Study of Fluconazole and Clotrimazole in the Treatment of Vulvovaginal Candidiasis, 582; Comparison and Evaluation of Nine Bibliographic Databases Concerning Adverse Drug Reactions, 1062; Comparison of Steady-State Serum Concentrations of Digoxin in Tablets (Lanoxin) and Capsules (Lanoxicaps) in the Elderly, 1043; Evaluation of a Non-Food and Drug Administration-Approved Use of Cimetidine: Treatment of Pruritus Resulting from Epidural Morphine Analgesia, 716; Evaluation of an Imipenem/Cilastatin Target Drug Program, 348; Gentamicin Pharmacokinetics in Postpartum Women with Endomyometritis, 1306; Improving Prescription-Writing Skills in a Family Practice Residency, 17; In Vitro Evaluation of Bleomycin-Induced Cell Lethality from Plastic and Glass Containers, 14; Intravenous or Intramuscular Teicoplanin Once Daily for Skin and Soft-Tissue Infections, 914; Mathematical Examination of Dual Individualization Principles (I): Relationships Between AUC Above MIC and Area Under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin, 1050; Mechanism of Interaction Between Theophylline and Mexiletine, 727; Meperidine Serum Concentrations and Analgesic Response in Postsurgical Patients, 724; Monitoring Serum Digoxin Concentrations During Digoxin Immune Fab Therapy, 1047; Patient Acceptance of Nordiject: A New Drug Delivery System for Growth Hormone, 585; Patterns of Nicotine Gum Use in a Health Maintenance Organization, 730; Pentamidine-Associated Nephrotoxicity and Hyperkalemia in Patients with AIDS, 1171; Pharmacist Interventions Improve Fluid Balance in Fluid-Restricted Patients Requiring Parenteral Nutrition, 119; Pharmacokinetic and Tolerance Evaluation of Actisomide, a New Antiarrhythmic Agent, in Healthy Volunteers, 231; Physical Compatibility and Chemical Stability of Amphotericin B in Combination with Magnesium Sulfate in 5% Dextrose Injection, 123; Retrospective Evaluation of Patient-Controlled Analgesia Use in a Large Teaching Institution, 1058; Steady-State Pharmacokinetics of Hydroxychloroquine in Rheumatoid Arthritis Patients, 1302; The Effect of Phenylpropanolamine on 24-Hour Blood Pressure in Normotensive Subjects Administered Indomethacin, 234; Toxicity of Colistin in Cystic Fibrosis Patients, 1168; Use of Albumin in a University Hospital: The Value of Targeted Physician Intervention, 239; Vancomycin Protein Binding in Patients with Infections Caused by *Staphylococcus aureus*, 713

Resistance, ceftazidime, *Pseudomonas aeruginosa* (L) 871

Resuscitation, cardiopulmonary, epinephrine, dosage (TC) 773, infants, children (TC) 760

Review Articles, Antiepileptic Medications in Development, 978; Are There Beta-Adrenergic Receptor Response Differences Between Racial Groups?, 824; BCG and the Treatment of Superficial Bladder Cancer, 1355; Changing Strategies in the Management of Chronic Congestive Heart Failure, 1349; Clinical Pharmacology of the Neuromuscular Blocking Agents, 54; Effect of Age on Lymphocyte Beta$_2$-Adrenergic Responsiveness, 532; Intradermal Hepatitis B Vaccination, 628; Is Heparin Really Necessary in the Lock, and, If So, How Much?, 399; Ketoconazole in the Treatment of Pityriasis Versicolor: International Review of Clinical Trials, 395; Misperceptions and Inadequate Pain Management in Cancer Patients, 1225; Monitoring Chronic Outpatient Infections: Providing Comprehensive Home Healthcare Pharmacy Services, 840; Overview of Biochemical Markers Used for Nutrition Support, 265; Overview of Synergy with Reference to Double Beta-Lactam Combinations, 972; Pharmacologic Treatment of Cocaine Abuse, 818; Purdue Stepped Approach Model: Application to Pharmacy Practice, 164; Reducing Time Delays in the Administration of Thrombolytic Therapy to Patients with Acute Myocardial Infarction, 1096; Safe Use of Codeine in the Recovering Alcoholic or Addict, 49; The Effect of Renal Failure on Hepatic Drug Clearance, 1214; The Postantibiotic Effect: A Review of In Vitro and In Vivo Data, 153; Therapeutic Advances in the Prevention of Hepatitis B: Yeast-Derived Recombinant Hepatitis B Vaccines, 617; Therapeutic Strategies for Myasthenia Gravis, 1101; Update on the Right to Refuse Antipsychotic Medication, 849; Vitamin D Therapy in Psoriasis, 835

Rhabdomyolysis, bezafibrate (L) 869

Rho Chi Lecture, Ideals and Innovation: Drugs, Generics, the FDA, and the Pharmacist, 427; Progress and Problems: A Personal Perspective, 1133

Rifampin, acute hemolysis, renal failure (SR) 743; postantibiotic effect (A) 154

Roxithromycin, pancreatitis (L) 1137

Rybak, Michael J., Fellow, ACCP (NC) 1038; Probus Club Award for Academic Achievement in Natural Sciences (NC) 1038

S

Saudi Arabia, package inserts, compared with US inserts (IR) 863; prescribing patterns, ambulatory care (IR) 90

Schentag, Jerome J., Russell R. Miller Award, ACCP (NC) 1038

Schizophyllan, immunoglobulin synthesis, *Staphylococcus aureus* (L) 101

Seizures, imipenem/cilastatin (CR) 351

Selegiline, compared with bromocriptine, Parkinson's disease (FF) 38; compared with methixene, Parkinson's disease (FF) 39; compared with tocopherol, Parkinson's disease (FF) 38; review (FF) 36

Sepsis, E5 monoclonal antibody, review (FF) 784; human monoclonal antibody, review (FF) 778

Sertraline, adverse reactions (FF) 957; compared with amitriptyline (FF) 954; interactions, review (FF) 958; pharmacokinetics (FF) 953; pharmacology (FF) 952; review (FF) 952

Shangraw, Ralph F., Distinguished Pharmacy Educator, Marion Merrell Dow (NC) 702

Short Reports, Acute Hemolysis and Renal Failure Following Discontinuous Use of Rifampin, 743; Altered Absorption of Digoxin, Sustained-Release Quinidine, and Warfarin with Sucralfate Administration, 745; Brachial Plexus Palsy with the Use of Haloperidol and a Geriatric Chair, 1072; Chemical Peritonitis Associated with Intraperitoneal Vancomycin, 602; Conversion of Intravenous Ranitidine to Oral Therapy, 251; Delirium in an Elderly Woman Possibly Associated with Administration of Misoprostol, 133; Digoxin Assay Anomalies Due to Digoxin-Specific Fab Immunotherapy, 739; Effect of I-Scrub on Signs and Symptoms of Chronic Blepharitis, 359; Eradication of Methicillin-Resistant *Staphylococcus aureus* Vaginitis with Mupirocin, 1331; Flutamide-Induced Methemoglobinemia, 600; Idioventricular Rhythm: Hypervagotonia Associated with Placebo, 471; In Vivo Inactivation of Tobramycin by Piperacillin, 357; Intravenous Enalaprilat Therapy for Hypertension, 25; Lidocaine Absorption and Metabolism After Oropharyngeal Application in Young and Young-Elderly Adults, 463; Local Tissue Reaction to Intravenous Fluorouracil, 249; Long-Term, Low-Dose Aspirin is Safe in Glucose-6-Phosphate Dehydrogenase Deficiency, 1074; Mania Associated with Clonazepam, 938; Medical Versus Pharmaceutical Continuing Education: Are Both Appropriate for the Pharmacist?, 1336; Naproxen-Induced Recurrent Aseptic Meningitis, 1183; Neuroleptic Malignant Syndrome Possibly Caused by Molindone Hydrochloride, 1071; Ofloxacin During the Second Trimester of Pregnancy, 1181; Possible Association of Pulmonary Fibrosis with Mexiletine, 1329; Procainamide-Induced Pseudo-Obstruction in a Diabetic Patient, 1334; Provocation Tests in a Chlorpromezanone-Induced Fixed Drug Eruption, 604; Stability of Ceftriaxone Sodium in Peritoneal Dialysis, 741; Stability of Labetalol Hydrochloride in Distilled Water, Simple Syrup, and Three Fruit Juices, 465; Successful Treatment of Neonatal *Citrobacter freundii* Meningitis with Ceftriaxone, 27; Thrombocytopenia Possibly Caused by Structurally Related Third-Generation Cephalosporins, 135; Urinary Retention—An Unusual Dystonic Reaction to Continuous Metoclopramide Infusion, 469; Urinary Retention Associated with Ipratropium Bromide, 939

Simvastatin, adverse reactions (FF) 261; compared with cholestyramine (FF) 260; compared with gemfibrozil (FF) 260; compared with probucol (FF) 260; pharmacokinetics (FF) 258; review (FF) 257

Smith, Gary H., USPC drug information development programs (NC) 450

Smith, William E., Ph.D. student, Auburn University (NC) 906

Society of Critical Care Medicine, pharmacist involvement (L) 1398

Society of Infectious Diseases Pharmacists, see **Association News (NC)**

Sodium bicarbonate, pediatric cardiopulmonary resuscitation (TC) 764

Software Reviews, reFORM Software, 106

Spain, antibiotics, utilization (IR) 662

Special Contributions, A Brief History of the "DIAS Rounds," 307; A Sketch of Donald E. Francke: Founder and First Editor, 425; Seventy Years in Retrospect, 1265; The Duty to Counsel: Reviewing a Decade of Litigation, 195; The Origins of the Clinical Pharmacy Program at the University of California, San Francisco, 308; The Pharm.D.: All or Some?, 94

Stability, ceftriaxone sodium, peritoneal dialysis (SR) 741; labetalol hydrochloride (SR) 465

***Staphylococcus aureus*,** immunoglobulin synthesis, schizophyllan (L) 101; methicillin-resistant, vaginitis, mupirocin (SR) 1331; prophylaxis, coronary bypass surgery (TC) 478; vancomycin, protein binding (RPR) 713

***Staphylococcus epidermidis*,** prophylaxis, coronary bypass surgery (TC) 478

Steroids, cortico-, asthma, review (PA) 72; compared with immune globulin, idiopathic thrombocytopenic purpura (DSP) 809; dosing, asthma (PA) 76; enemas, compared with mesalamine enemas (FF) 142; meningitis, infants, children (PED) 542; myasthenia gravis (A) 1104; toxicity, asthma (PA) 77

Streptokinase, administration delay, myocardial infarction (A) 1096; compared with alteplase (L) 1271; neonatal thrombosis (PED) 853

Streptomycin, availability (NC) 1430

Succinylcholine, pharmacodynamics (A) 57; pharmacokinetics (A) 57; with ketamine, intubation, children (DIAS) 475

Sucralfate, interaction, ciprofloxacin (RPR) 578, digoxin/quinidine/warfarin (SR) 745, quinolones (DIR) 1254

Sulfamethoxazole, with trimethoprim, *Pneumocystis carinii* pneumonia (DIAS) 941

Sulfasalazine, oral, compared with mesalamine enemas (FF) 142

Sulfonamides, postantibiotic effect (A) 154

Surgery, coronary bypass, antibiotic prophylaxis (TC) 478

Sympatholytic agents, adverse reactions, review (DSP) 969; age (A) 532; alcohol withdrawal (DIAS) 31; beta-adrenergic receptor response, racial groups (A) 824; pharmacokinetics (DSP) 964; pharmacology (DSP) 962

Sympathomimetic agents, age (A) 532; asthma, review (PA) 997; beta-adrenergic receptor response, racial groups (A) 824

Systemic lupus erythematosus, drug-induced, review (L) 212

T

Tachycardia, supraventricular, adenosine (DIAS) 749

Talc, compared with bleomycin, malignant pleural effusion (DIAS) 1188; compared with tetracycline, malignant pleural effusion (DIAS) 1188; malignant pleural effusion (DIAS) 1187

Taste, alteration, meperidine (L) 1137

Teicoplanin, intravenous compared with intramuscular, skin, soft-tissue infection (RPR) 914

Teratogenicity, ofloxacin (SR) 1181; phenytoin (PED) 987

Testosterone, topical, microphallus (DIAS) 1341

Tetanus toxoid, anaphylaxis (L) 870

Tetracycline, compared with talc, malignant pleural effusion (DIAS) 1188; postantibiotic effect (A) 154

Thallous chloride, stress imaging, dipyridamole (FF) 1085

Theophylline, asthma, review (PA) 998; clearance, cystic fibrosis (L) 212, kidney failure (A) 1219; concentrations, compliance (L) 103; dosage, pediatrics (PED) 179; interaction, ciprofloxacin, computer monitoring (L) 1011, mexiletine (RPR) 727, quinolones, meta-analysis (DIR) 191, ranitidine (CR) 21; metabolism, ranitidine inhibition (L) 1139; nebulized, ventilator parameters, neonates (PED) 273

Therapeutic Controversies, Activated Charcoal and Acetylcysteine Absorption: Issues in Interpreting Pharmacokinetic Data, 1081; Antimicrobial Prophylaxis in Coronary Bypass Surgery: A Critical Appraisal, 478; Controversies in Cardiopulmonary Resuscitation: Pediatric Considerations, 760; Indomethacin for Prevention of Neonatal Intraventricular Hemorrhage, 1344; Leukemia in Bipolar Mood Disorder: Is Lithium Contraindicated?, 948; The Controversy of Heparin Therapy as an Adjunct to Thrombolysis in Acute Myocardial Infarction, 613; The Dose of Epinephrine During Cardiopulmonary Resuscitation in Humans: What Should It Be?, 773; Warfarin and the International Normalized Ratio: Reducing Interlaboratory Effects, 1190

Therapeutic monitoring, procainamide, neonates (PED) 68

Therapeutic Monitoring (TM), Early Individualization of Tricyclic Antidepressant Dosing Using a Bayesian Pharmacokinetic Model, 1368; Three-Point Versus Two-Point Method for Early Individualization of Aminoglycoside Doses, 635

Thiethylperazine, neuroleptic malignant syndrome (L) 1007

Thiotepa, superficial bladder cancer (A) 1357

Thompson, Dennis F., USPC drug information devlopment programs (NC) 450

Thrombocytopenia, ceftazidime, ceftriaxone (SR) 135; famotidine (L) 678; mechanism (L) 874

Thrombocytopenic purpura, idiopathic, immune globulin, review (DSP) 808

Thrombolytic agents, administration delay, myocardial infarction (A) 1096

Thrombosis, acute myocardial infarction, heparin (TC) 613; deep vein, therapy institution (L) 1397; neonatal, heparin, thrombolytics (PED) 853

Ticarcillin, postantibiotic effect (A) 155

Timolol, pharmacokinetics (DSP) 965

Tizanidine, interaction, phenytoin (L) 1273

Tobramycin, interaction, piperacillin (SR) 357; pharmacokinetics, bacterial susceptibility (RPR) 1050; postantibiotic effect (A) 156

Tocainide, clearance, kidney failure (A) 1218

Tocopherol, compared with selegiline, Parkinson's disease (FF) 38

Tolerance, actisomide (RPR) 231; cancer patients (A) 1226; isosorbide dinitrate (L) 1272

Toxicity, colistin, cystic fibrosis (RPR) 1168; colony-stimulating factors (DSP) 492; corticosteroids, asthma (PA) 77; diphenhydramine, varicella zoster (CR) 130; ephedrine, hypertensive crisis (CR) 1068; fludarabine (FF) 522; gamma hydroxy butyrate (NC) 114; 3-hydroxyquinidine (L) 867; idarubicin (FF) 512; interleukin-2 (DSP) 494; lead (CR) 932; nonsteroidal antiinflammatory drugs, overdose (CR) 1066; oxymetazoline, hypertensive crisis (CR) 1068; phenylephrine, hypertensive crisis (CR) 1068; phenytoin, pharmacokinetics, activated charcoal (PED) 646; tryptophan, epidemiology (PEP) 1259; vitamin D (A) 837; water, carbamazepine/phenobarbital overdose (CR) 354

TOXLINE, compared with EMBASE, MEDLINE, BIOSIS, IDIS, Core MEDLINE, PASCAL PHARMLINE, IPA, adverse drug reactions (RPR) 1062

Transplantation, renal, amantadine, neurotoxicity (CR) 1175

Tranylcypromine sulfate, attention deficit disorder with hyperactivity (DSP) 1209; MAO inhibition (L) 99

Trazodone, cocaine abuse (A) 819

Triazolam, market removal (E) 1263

Triglycerides, biochemical markers, nutrition support (A) 265

Trimethobenzamide, neuroleptic malignant syndrome (L) 1007

Trimethoprim, postantibiotic effect (A) 154; with sulfamethoxazole, *Pneumocystis carinii* pneumonia (DIAS) 941

Tryptophan, eosinophilia–myalgia syndrome, epidemiology (PEP) 1259

Tuberculin, purified protein derivative, elderly (G) 650

Tuberculosis, ciprofloxacin (RPR) 919; elderly, review (G) 650

Tyrosine, cocaine abuse (A) 820

U

Ulcers, decubitus, home care (A) 847

University of California, San Francisco, clinical pharmacy program (SC) 308

Urinary disorders, retention, ipratropium bromide (SR) 939, metoclopramide (SR) 469

Urokinase, neonatal thrombosis (PED) 853

Urticaria, idiopathic, cimetidine (DIAS) 609

USPHS–CDC News (NC), Acute Allergic Reactions Associated with Reprocessed Hemodialyzers—US, 1989-90, 572; AIDS in Europe, 114; AIDS in Women, 114; Cholera in the Western Hemisphere: Update and Recommendations for Treatment, 1294; Discontinuation of Parenteral Quinine from CDC, 906; Measles Vaccination Levels Among Preschool-Aged Children, 338; Mefloquine Dosing Regimen Changed, 450; Mortality Attributable to HIV Infection/AIDS, 338; Poisonings Associated with Illicit use of Gamma Hydroxy Butyrate, 114; Preventing Transmission of HIV and Hepatitis B Virus, 1157; Publicly Funded HIV Counseling and Testing—US, 1990, 1430; Streptomycin and Para-Aminosalicylic Acid, 1430; Treatment of Severe *Plasmodium falciparum* Infection with Quinidine Gluconate, 906; Tuberculosis and HIV Infection: Anergy Testing and Patient Management, 1038

USPHS News (NC), Pharmacy Consultation Program Available, 905

V-Z

Vancomycin, peritonitis (SR) 602; postantibiotic effect (A) 154; protein binding, *Staphylococcus aureus* (RPR) 713; rash (CR) 1326; removal, hemofiltration (CR) 127

Vaginitis, methicillin-resistant *Staphylococcus aureus*, mupirocin (SR) 1331

Vapreotide, analgesia (L) 1136

Varicella-zoster, diphenhydramine toxicity (CR) 130

Vasodilating drugs, congestive heart failure, review (A) 1351

Vecuronium, pharmacodynamics (A) 58; pharmacokinetics (A) 59

Verapamil, clearance, kidney failure (A) 1216; compared with adenosine, supraventricular tachycardia (DIAS) 749; migraine prophylaxis (DIAS) 1076; premenstrual syndrome (DIAS) 361

Vidarabine, interaction, pegademase bovine, review (FF) 1094

Vigabatrin, pharmacokinetics (A) 979; review (A) 984

VIP News (NC), Abate, Marie A., 450; Baker, Danial E., 450; Beck, Diane E., 572; Benet, Leslie Z., 572; Campbell, R. Keith, 1038; Carmichael, Jannet M., 1431; Clayton, Anne G., 572; Covington, Timothy R., 1431; Edwards, David J., 1038; Emswiller, Carl F. Jr., 1431; Finley, Rebecca S., 1431; Graves, Nina M., 1038; Hart, Linda L., 450; Kaul, Alan F., 1431; Kelly, William N., 1431; Knapp, David A., 906; Lake, Kathleen D., 450; Lamp, Kenneth, 1038; Lopez, Larry M., 1038; McGhan, William F., 450, 906; Nahata, Milap C., 572; Ponte, Charles D., 572; Rybak, Michael J., 1038; Schentag, Jerome J., 1038; Shangraw, Ralph F., 702; Smith, Gary H., 450; Smith, William E., 906; Thompson, Dennis F., 450

Vitamin D, psoriasis (DIAS) 753, review (A) 835; toxicity (A) 837

Vitamin E, anticonvulsant (DIAS) 362

Vitamin K_1, anaphylaxis (L) 871

Volmax, release rate (L) 438

Wagner, John G., career retrospective (SC) 1265

Warfarin, interaction, ciprofloxacin (L) 1397, nafcillin (CR) 598; international normalized ratio, interlaboratory effects (TC) 1190; therapy institution, deep vein thrombosis (L) 1397; with digoxin/quinidine, interaction, sucralfate (SR) 745

Withdrawal, see **Drug withdrawal**

Women, AIDS, incidence (NC) 114

Xamoterol, congestive heart failure, review (A) 1352

Zidovudine, clearance, kidney failure (A) 1217; utilization (PEP) 1374

Zimbabwe, drug information center, establishment (IR) 1379; pharmacy education, practice (IR) 302

Zinc, interaction, quinolones (DIR) 1253

AUTHOR INDEX

A-B

Abel, Steven R. (author) Evaluation of an Imipenem/Cilastatin Target Drug Program (RPR) 348

Abou-Auda, Hisham S. (coauthor) see **Bawazir, Saleh A.,** 863

Ackerman, Bruce H. (author) Accumulation of 3-Hydroxyquinidine Following Chronic Quinidine Therapy (L) 867; (author) book review, 1401; (author) Monitoring Chronic Outpatient Infections: Providing Comprehensive Home Healthcare Pharmacy Services (A) 840

Adair, Colin G. (author) book review, 878

Adelman, Martin H. (coauthor) see **Schentag, Jerome J.,** 1050

Ahmad, Saeed (author) Enalapril-Induced Acute Psychosis (L) 558; (author) Famotidine and Cardiac Arrhythmia (L) 315; (author) Fluoxetine and Glaucoma (L) 436

Ajileye, Isaac (coauthor) see **Hitchen, Karen,** 1398

Albrecht, Lisa M. (author) Vancomycin Protein Binding in Patients with Infections Caused by *Staphylococcus aureus* (RPR) 713

Alerany, Carmen (coauthor) see **Zara, Corinne,** 662

Alexander, Bruce (coauthor) see **Perry, Paul J.,** 1270

Alexander, Michael R. (author) Comment: Pharm.D.: All or Some? (L) 1400

Al-Hassan, Mohammed I. (coauthor) see **Bawazir, Saleh A.,** 863

Al-Khamis, Khalil I. (coauthor) see **Bawazir, Saleh A.,** 863

Allen, Nancy M. (author) Clinical and Pharmacokinetic Profiles of Digoxin Immune Fab in Four Patients with Renal Impairment (CR) 1315

Al-Nasser, Abdulaziz N. (author) Prescribing Patterns in Primary Healthcare in Saudi Arabia (IR) 90

Alonso, Kenneth (coauthor) see **Stajich, Gregory V.,** 14

Alsar, Maria Jesús (coauthor) see **Alvarez, Javier Soto,** 558, 1397

Altimiras, Juan (coauthor) see **Duque, Alberto,** 1009

Alvarez, Javier Soto (author) Aminoglycosides: Determination of New Therapeutic Ranges (L) 558; (author) Interferon Alfa-2a-Induced Impotence (L) 1397

Amarshi, Naseem (coauthor) see **Peery, Patrick A.,** 1137

Amato, Mary G. (author) book review, 683

Aoki, Fred Y. (coauthor) see **Grymonpre, Ruby E.,** 186

Appelt, Glenn D. (author) book review, 216

Araujo, Oscar E. (author) Vitamin D Therapy in Psoriasis (A) 835

Arbus, Gerald S. (coauthor) see **Strong, Dawn K.,** 1175

Ariano, Robert E. (author) Antimicrobial Prophylaxis in Coronary Bypass Surgery: A Critical Appraisal (TC) 478

Arnau, Josep Maria (coauthor) see **Balague, Montserrat,** 871

Artoux, Michelle J. (author) Alprostadil in Impotence (DIAS) 363

Aumaitre, Olivier (author) Preliminary Clinical Evidence for Analgesic Effect of Vapreotide (L) 1136; (coauthor) see **Souweine, B.,** 1137

Autret, Elisabeth (coauthor) see **Jonville, Annie-Pierre,** 1113

Avisar, Rahamim (author) Effect of I-Scrub on Signs and Symptoms of Chronic Blepharitis (SR) 359

Baciewicz, Anne M. (author) Conversion of Intravenous Ranitidine to Oral Therapy (SR) 251

Badir, Amin (coauthor) see **Malnick, Stephen D.H.,** 869

Bahal, Neeta (author) The Role of Corticosteroids in Infants and Children with Bacterial Meningitis (PED) 542

Bailie, George R. (coauthor) see **Briceland, Laurie L.,** 1171; (coauthor) see **Lomaestro, Ben M.,** 1249; (coauthor) see **Smith, Thomas A. II,** 602

Baker, Danial E. (coauthor) see **Garrison, Mark W.,** 617

Balagué, Montserrat (author) *Pseudomonas aeruginosa* Resistance to Ceftazidime (L) 871

Ballow, Charles H. (coauthor) see **Leo, Raphael J.,** 351

Balmer, Carol McManus (author) Clinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview. Part II. Colony-Stimulating Factors and Interleukin-2 (DSP) 490

Baltz, Julie K. (coauthor) see **Minor, James R.,** 41

Baptista, Richard J. (coauthor) see **Driscoll, David F.,** 276

Barbarash, Rick A. (author) Correction: Mechanical Ventilation (L) 1017

Barber, Peter G. (coauthor) see **Etzel, Joseph V.,** 1341

Barbier, Pascaline (coauthor) see **Jonville, Annie-Pierre,** 1113

Barlow, Jared C. (coauthor) see **Watson, William A.,** 463

Barreuther, Alan D. (coauthor) see **Raisch, Dennis W.,** 716

Batty, Kevin T. (author) Evaluation of Generic–Brand Name Knowledge (L) 1138

Baumann, Terry J. (author) Meperidine Serum Concentrations and Analgesic Response in Postsurgical Patients (RPR) 724

Bavoux, Françoise (coauthor) see **Jonville, Annie-Pierre,** 1113

Bawazir, Saleh A. (author) Comparative Study of Saudi-Marketed Products and US Drug Labeling (IR) 863

Beardsley, Robert S. (coauthor) see **Hohmann, Ann A.,** 85

Beckley, Dennis J. (coauthor) see **Edelstein, Howard E.,** 1007

Bégaud, Bernard (coauthor) see **Haramburu, Francoise,** 214, 875

Beijnen, Jos H. (author) Visual Compatibility of Ondansetron and Dexamethasone (L) 869

Belitsky, Philip (coauthor) see **Dugandzic, Rose M.,** 316

Bell, Charles N., Jr. (coauthor) see **Rae, Charlesworth E.,** 932

Bell, Jeffrey M. (coauthor) see **Peterson, Andrew M.,** 1334

Ben-Amitai, Dan (author) Neonatal Fever and Cyanotic Spells from Maternal Chlorpromazine (L) 1009

Benet, Leslie Z. (author) Ideals and Innovation: Drugs, Generics, the FDA, and the Pharmacist (RC) 427

Ben-Noun, Liubov (author) Unresponsiveness to Nifedipine Treatment (L) 99

Benson, Jill M. (author) The Impact of Changing Ventilator Parameters on Availability of Nebulized Drugs in an In Vitro Neonatal Lung System (PED) 272

Berardi, Rosemary R. (coauthor) see **Kirking, Duane M.,** 80, 682

Berg, Mary J. (coauthor) see **Van Dyke, Don C.,** 987

Berman, Alex (author) book review, 683

Bero, Christopher J. (author) Possible Association of Pulmonary Fibrosis with Mexiletine (SR) 1329

Bertrand, Philippe (coauthor) see **Jonville, Annie-Pierre,** 1113

Biarez, Odile (author) Comparison and Evaluation of Nine Bibliographic Databases Concerning Adverse Drug Reactions (RPR) 1062

Bistrian, Bruce R. (coauthor) see **Driscoll, David F.,** 276

Bivins, Brack A. (coauthor) see **Baumann, Terry J.,** 724

Bjornson, Darrel C. (author) The Relationship Between Outpatient Drug Costs and Disease Progression in the Human Immunodeficiency Virus-Infected Population (PEC) 414

Black, David R. (author) Purdue Stepped Approach Model: Application to Pharmacy Practice (A) 164

Blackburn, George L. (coauthor) see **Driscoll, David F.,** 276

Blume, Robert P. (coauthor) see **Keys, Patricia A.,** 1101

Blumer, Jeffrey L. (coauthor) see **Buck, Marcia L.,** 244; (coauthor) see **Reed, Michael D.,** 344

Bogaert, Marc G. (coauthor) see **Vander Stichele, Robert H.,** 1002

Bollini, Paola (coauthor) see **Muscettola, Giovanni,** 296

Bond, William S. (author) Pharm.D.: All or Some? (L) 679

Bootman, J. Lyle (coeditor) see McGhan, William F., 80, 289, 414, 546

Bosso, John A. (author) Academic Pharmacy Practice and Research (E) 1129; (author) Toxicity of Colistin in Cystic Fibrosis Patients (RPR) 1168

Brady, Silvia I. (author) Calcitonin in Migraine (DIAS) 1185; (author) Topical Aspirin for Postherpetic Neuralgia (DIAS) 1077

Braem, Marc D. (coauthor) see **Vander Stichele, Robert H.,** 1002

Brambilla, Donald J. (coauthor) see **Hemminki, Elina,** 418

Brandon, Donald (coauthor) see **Hull, Robert Lee,** 135

Bressler, Linda R. (author) Misperceptions and Inadequate Pain Management in Cancer Patients (A) 1225

Brett, Judy L. (coauthor) see **Foran, Robert M.,** 546

Briceland, Laurie L. (author) Cost Considerations of Conversion from Aminoglycoside-Containing Combination Regimens to Ceftriaxone (L) 319; (author) Pentamidine-Associated Nephrotoxicity and Hyperkalemia in Patients with AIDS (RPR) 1171

Briggs, Gerald G. (author) book review, 1017

Bright, Thomas P. (author) Suspected Central Nervous System Toxicity from Inadvertent Nonsteroidal Antiinflammatory Drug Overdose (CR) 1066

Bromley, Howard R. (coauthor) see **Uber, Walter E.,** 357

Brown, Candace S. (author) Treatment of Attention Deficit Hyperactivity Disorder: A Critical Review (DSP) 1207

Brown, KimDebra (coauthor) see **Araujo, Oscar E.,** 835

Brown, Rex O. (coauthor) see **Broyles, Joyce E.,** 119

Broyles, Joyce E. (author) Pharmacist Interventions Improve Fluid Balance in Fluid-Restricted Patients Requiring Parenteral Nutrition (RPR) 119

Brundage, Dianne M. (coauthor) see **Uber, Walter E.,** 357

Brundage, Richard C. (coauthor) see **Uber, Walter E.,** 357

Brushwood, David B. (author) The Duty to Counsel: Reviewing a Decade of Litigation (SC) 195

Brusko, Cynthia S. (author) Ketoconazole Hepatotoxicity in a Patient Treated for Environmental Illness and Systemic Candidiasis (CR) 1321

Bryson, Scott M. (author) Therapeutic Monitoring and Pharmacokinetic Evaluation of Procainamide in Neonates (PED) 68; (coauthor) see **Strong, Dawn K.,** 1175

Buck, Marcia L. (author) Phenothiazine-Associated Apnea in Two Siblings (CR) 244; (author) Prostaglandin E_1 Treatment of Congenital Heart Disease: Use Prior to Neonatal Transport (PED) 408

C-D

Campbell, G. Douglas, Jr. (coauthor) see **Olsen, Keith M.,** 784

Canals, Antonio Mirada (author) Methyldopa-Induced Granulomatous Hepatitis (L) 1269

Cantú, Thomas G. (author) Caffeine in Electroconvulsive Therapy (DIAS) 1079

Cardoni, Alex A. (author) Pharm.D.: All or Some? (L) 679

Carter, Charles A. (author) book review, 1275

Cassano, Karen B. (coauthor) see **Edelstein, Howard E.,** 914

Catala, Jesus (coauthor) see **Sanchis, Amparo,** 1137

Cerdà-Trias, MªTeresa (coauthor) see **Lleonart-Bellfill, Ramon,** 870

Cetnarowski-Cropp, Anne B. (author) Quinapril: A New Second-Generation ACE Inhibitor (FF) 499

Chaffee, Bruce W. (coauthor) see **Kirking, Duane M.,** 80, 682

Chan, C.Y. Jennifer (author) Diphenhydramine Toxicity in Three Children with Varicella-Zoster Infection (CR) 130

Chan, Cheng L. (coauthor) see **Chow, Moses S.S.,** 613

Chan, Gary L. (author) Effect of Plasmapheresis on Cyclosporine Pharmacokinetics (L) 211

Chareyre, Stéphane (coauthor) see **Schott, Anne Marie,** 600

Chirurgi, Valerie A. (coauthor) see **Edelstein, Howard E.,** 914, 1007

Chow, Moses S.S. (author) The Controversy of Heparin Therapy as an Adjunct to Thombolysis in Acute Myocardial Infarction (TC) 613

Choy, Melissa (author) Cimetidine in Idiopathic Urticaria (DIAS) 609

Chrischilles, Elizabeth A. (coauthor) see **Semla, Todd P.,** 410

Christensen, Sharon (coauthor) see **Stein, Gary E.,** 582

Cisteró-Bahima, Anna (coauthor) see **Lleonart-Bellfill, Ramon,** 870

Cocchetto, David M. (coauthor) see **Rue, Peter J.,** 438

Colbert, James, Jr. (author) We Use Drugs Too—More Pediatric Information in Review Articles (L) 559

Collin, Kathleen (coauthor) see **Levine, Marc,** 743

Colucci, Robert D. (coauthor) see **Ujhelyi, Michael R.,** 1047

Conner, Dale P. (author) book review, 217

Conrad, Stephen D. (coauthor) see **Peterson, Andrew M.,** 1334

Cool-Foley, Alicia A. (author) Eradication of Methicillin-Resistant *Staphylococcus aureus* Vaginitis with Mupirocin (SR) 1331

Corelli, Robin L. (author) Medication Usage Patterns in Pa-

tients with Human Immunodeficiency Virus Infection: A Comparison of Patient Reported Medication Usage with Medical Chart Review (PEP) 1374
Cornish, Laura A. (coauthor) see **Kirking, Duane M.**, 80, 682
Coulston, Daniel R. (author) Hepatitis B Vaccine (O) 671
Craft, Alan W. (coauthor) see **Kohli-Kumar, Mudra**, 469
Crismon, M. Lynn (coauthor) see **Volf, Nora**, 948
Cummings, Doyle M. (coauthor) see **Ujhelyi, Michael R.**, 1047
Curet, Luis B. (coauthor) see **Gauger, Laura J.**, 456
Curry, Monica L. (author) Interaction of Phenothiazine and Related Drugs and Caffeinated Beverages (L) 437
Curry, Stephen H. (coauthor) see **Curry, Monica L.**, 437
Cutler, Neal R. (author) Idioventricular Rhythm: Hypervagotonia Associated with Placebo (SR) 471
Czachor, John S. (coauthor) see **Dallal, Mohammed M.**, 594
Dallal, Mohammed M. (author) Aztreonam-Induced Myelosuppression During Treatment of *Pseudomonas aeruginosa* Pneumonia (CR) 594
D'Amico, Frank (coauthor) see **Shaughnessy, Allen F.**, 17
Danziger, Larry H. (coauthor) see **Shwed, Jill A.**, 10
Dasta, Joseph F. (author) book review, 105; (author) Pharmacist Involvement in Society of Critical Care Medicine (L) 1398; (editor) Critical Care Therapeutics, 169, 276, 1231
Davies, John M. (coauthor) see **Gilleece, Maria H.**, 867
Davis, Robin L. (coauthor) see **Raymond, Glynn G.**, 123
Day, Robert L. (author) Authors' Reply: Origins of Clinical Pharmacy (L) 1142; (author) The Origins of the Clinical Pharmacy Program at the University of California, San Francisco (SC) 308
Dean, Richard R. (coauthor) see **Malesker, Mark A.**, 231
Decker, David A. (coauthor) see **Umstead, Greg S.**, 249
DeJong, Douglas J. (coauthor) see **Sayler, Debra J.**, 436
Delgadillo, Joaquim (coauthor) see **Nafria, Esteve Colomé**, 870
Delgado, Fernando (coauthor) see **Martinez-Abad, Manuel**, 871
Delmas, Pierre D. (coauthor) see **Schott, Anne Marie**, 600
Del Valle, Oscar (coauthor) see **Balague, Montserrat**, 871
Destache, Christopher J. (coauthor) see **Malesker, Mark A.**, 231
Deutsch, David (coauthor) see **Avisar, Rahamim**, 359
Dielman, Debra G. (coauthor) see **McCullough, Jill M.**, 1326
Dolgin, Jill G. (author) Pharmacokinetic Simulation of the Effect of Multiple-Dose Activated Charcoal in Phenytoin Poisoning—Report of Two Pediatric Cases (PED) 646
Dordain, Gerard (coauthor) see **Aumaitre, Olivier**, 1136
Doreau, Christian G. (coauthor) see **Biarez, Odile**, 1062
Dorevitch, Abraham (author) Mania Associated with Clonazepam (SR) 938
Draugalis, JoLaine R. (coauthor) see **Jones-Grizzle, Amy J.**, 289
Drees, Christine A. (author) Aseptic Meningitis and Muromonab-CD3 Therapy (DIAS) 138
Driscoll, David F. (author) Parenteral Nutrient Admixtures as Drug Vehicles: Theory and Practice in the Critical Care Setting (CC) 276
Driver, Paul S. (author) Depression Treatment in Parkinson's Disease (DIAS) 137
Duchene-Marullaz, Pierre (coauthor) see **Aumaitre, Olivier**, 1136
Dugandzic, Rose M. (author) Effect of Coadministration of Acyclovir and Cyclosporine on Kidney Function and Cyclosporine Concentrations in Renal Transplant Patients (L) 316
Dugoni-Kramer, Bonnie M. (author) Ciprofloxacin–Warfarin Interaction (L) 1397
Dukes, George E. (coauthor) see **Graham, Lynn**, 1275
Dunham, Gary D. (coauthor) see **Allen, Nancy M.**, 1315
Dunn, Marvin I. (coauthor) see **Howard, Patricia A.**, 929
Dupuis, Robert E. (coauthor) see **Roush, Maura Kraynak**, 473
Duque, Alberto (author) Vertigo Caused by Intravenous Imipenem/Cilastatin (L) 1009

E-F

Edelstein, Howard E. (author) Adverse Reactions to Phenothiazine Antiemetics in AIDS (L) 1007; (author) Intravenous or Intramuscular Teicoplanin Once Daily for Skin and Soft-Tissue Infections (RPR) 914
Edmunds, Marilyn W. (author) book review, 1018
Edwards, David J. (coauthor) see **Albrecht, Lisa M.**, 713; (coauthor) see **Touchette, Mark A.**, 104
Edwards, George A. (coauthor) see **Godley, Paul J.**, 179
Eisele, George (coauthor) see **Smith, Thomas A. II**, 602
Eisenstat, David D. (coauthor) see **Strong, Dawn K.**, 1175
Elis, Avishay (author) Agranulocytosis Associated with Enalapril (CR) 461
Elliott, Clyde E. (coauthor) see **Rae, Charlesworth E.**, 932
Engen, Phillip L. (coauthor) see **Howard, Patricia A.**, 929
Erdman, Sharon M. (author) Trimethoprim/Sulfamethoxazole Concentrations in *Pneumocystis carinii* Pneumonia (DIAS) 941
Erickson, Steven R. (author) Hypotension and Bradycardia Possibly Associated with Intraocular Injection of Acetylcholine (CR) 1178
Eschalier, Alain (coauthor) see **Aumaitre, Olivier**, 1136
Eselin, Julie (author) Talc in the Treatment of Malignant Pleural Effusion (DIAS) 1187
Espinach, Joan (coauthor) see **Nafria, Esteve Colomé**, 870
Etienne, Jean (coauthor) see **Biarez, Odile**, 1062
Etzel, Joseph V. (author) Topical Uses of Testosterone (DIAS) 1341
Ewing, James R. (coauthor) see **Fagan, Susan C.**, 1299
Fagan, Susan C. (author) Assessing the Effects of Antihypertensive Medication on Cerebral Blood Flow: Demonstration in Internal Carotid Artery Occlusion (RPR) 1299; (author) Nimodipine and Bradycardia in Acute Stroke—Drug or Disease? (CR) 247
Faulkner, Thomas P. (coauthor) see **Gundlach, Catherine A.**, 1231
Fazio, Anthony (coauthor) see **Rae, Charlesworth E.**, 27
Feld, Steven (coauthor) see **Shapira, Oz M.**, 354
Felts, Nancy (coauthor) see **Peery, Patrick A.**, 1137
Fialip, Joseph (coauthor) see **Aumaitre, Olivier**, 1136; (coauthor) see **Souweine, B.**, 1137
Fiedler, Jill B. (coauthor) see **Grasela, Thaddeus H. Jr.**, 857
Fields, Suzanne M. (author) Idarubicin: A Second-Generation Anthracycline (FF) 505
Figg, William D. (author) Aseptic Meningitis Associated with Muromonab-CD3 (L) 1395; (author) Peripheral Neuropathy in HIV Patient After Isoniazid (L) 100; (coauthor) see **O'Quinn, Stephen V.**, 1272; (coauthor) see **Williams, Dennis M.**, 1140
Figueras, Albert (coauthor) see **Balague, Montserrat**, 871
Findlay, John W.A. (coauthor) see **Allen, Nancy M.**, 1315
Finley, Rebecca S. (coauthor) see **Hood, Michele A.**, 518
Fitzgerald, Jill Mancini (author) Authors' Reply: Mesalamine in Ulcerative Colitis (L) 1015; (author) Mesalamine in Ulcerative Colitis (FF) 140
Flowers, Franklin P. (coauthor) see **Araujo, Oscar E.**, 835; (coauthor) see **Goodless, Dean R.**, 395
Flowers, Melinda K. (coauthor) see **Taylor, David M.**, 212
Floyd, Ronald A. (author) Comment: Aminoglycoside Dosing (L) 1141
Fogarty, Patricia M. (coauthor) see **Hennessy, Sean**, 678
Fonollosa, Vincenç (coauthor) see **Nafria, Esteve Colomé**, 870
Foran, Robert M. (author) Evaluating the Cost Impact of Intravenous Antibiotic Dosing Frequencies (PEC) 546
Franson, Kari L. (author) Cyclosporine in Graves' Ophthalmopathy (DIAS) 750
Friedman, Shmuel (coauthor) see **Peled, Yoav**, 1181
Froese, Emerson H. (coauthor) see **Jameson, John P.**, 302
Fryer, Nancy L. (coauthor) see **Umstead, Greg S.**, 249
Fujita, Takuo (coauthor) see **Shiozawa, Shunichi**, 101
Fuller, Dennis K. (coauthor) see **Levinson, Miriam L.**, 657
Fuller, Matthew A. (author) Selegiline: Initial or Adjunctive Therapy of Parkinson's Disease (FF) 36

G-H

Gal, Peter (author) Indomethacin Therapy for Intraventricular Hemorrhage in Neonates: Another Use for that "Old" Drug (E) 1385; (author) Neonatal Thrombosis: Treatment with Heparin and Thrombolytics (PED) 853; (coauthor) see **Benson, Jill M.**, 272
Galinsky, Raymond E. (author) Pharmacists and the Mandate of Pharmaceutical Care (O) 431
Gandhi, Dipeshkumar K. (coauthor) see **Cutler, Neal R.**, 471
Gannon, Joan M. (coauthor) see **Hilleman, Daniel E.**, 1096
Gannon, Patrick M. (coauthor) see **Sesin, G. Paul**, 872
Garcia-Cases, Carlos (coauthor) see **Duque, Alberto**, 1009
Gardner, Stephanie F. (author) Medical Versus Pharmaceutical Continuing Education: Are Both Appropriate for the Pharmacist? (SR) 1336
Garrelts, James C. (author) Clofazimine: A Review of Its Use in Leprosy and *Mycobacterium avium* Complex Infection (FF) 525
Garrison, Mark W. (author) Therapeutic Advances in the Prevention of Hepatitis B: Yeast-Derived Recombinant Hepatitis B Vaccines (A) 617
Gauchez, Anne-Sophie M. (coauthor) see **Jonville, Annie-Pierre**, 1113
Gauger, Laura J. (author) Comparative Efficacy of Intravaginal Prostaglandin E_2 in the Gel and Suppository Forms for Cervical Ripening (RPR) 456
Geraci, Mark C. (coauthor) see **Bressler, Linda R.**, 1225
Ghanem, Jihad (coauthor) see **Heyman, Samuel N.**, 1068
Gibson, Gene A. (coauthor) see **Munar, Myrna Y.**, 1306
Gilbert, Robert P. (coauthor) see **Hegman, Greg W.**, 21
Gilleece, Maria H. (author) Mesna Therapy and Hypertension (L) 867
Gilman, Jamie T. (author) Carbamazepine Dosing for Pediatric Seizure Disorders: The Highs and Lows (PED) 1109
Givner, Morris L. (coauthor) see **Dugandzic, Rose M.**, 316
Glazier, Howard S. (author) Comment: Parenteral H_2-Receptor Antagonist Intervention (L) 681
Glenarkis, Dean G. (author) Ketorolac Formulary Restriction and Usage Evaluation (L) 1399
Gloudeman, Mark W. (coauthor) see **Edelstein, Howard E.**, 1007
Goad, Janet D. (coauthor) see **Kucukarslan, Suzan N.**, 213
Godin, Marie-Hélène (coauthor) see **Haramburu, Francoise**, 214, 875
Godley, Paul J. (author) Evaluation of Three Theophylline Dosing Methods in Pediatric Patients (PED) 179; (coauthor) see **Wasan, Suman M.**, 942
Godley, Susan E. (coauthor) see **Godley, Paul J.**, 179
Goldspiel, Barry R. (author) Goserelin Acetate Implant: A Depot Luteinizing Hormone-Releasing Hormone Analog for Advanced Prostate Cancer (FF) 796; (coauthor) see **Kohler, David R.**, 367
Goldstein, Harvey R. (coauthor) see **Van Slooten, Andrea D.**, 578
Gonzalez, Edgar R. (author) The Dose of Epinephrine During Cardiopulmonary Resuscitation in Humans: What Should It Be? (TC) 773
Gooch, W. Manford, III (coauthor) see **Reed, Michael D.**, 344
Goodless, Dean R. (author) Ketoconazole in the Treatment of Pityriasis Versicolor: International Review of Clinical Trials (A) 395
Goodman, Robert P. (coauthor) see **McKenney, James M.**, 234
Goswami, Amar (coauthor) see **Olson, Lisa A.**, 100
Goyan, Jere E. (coauthor) see **Day, Robert L.**, 308, 1142
Gozzo, Isabelle (coauthor) see **Schott, Anne Marie**, 600
Gradon, Jeremy D. (author) Neuroleptic Malignant Syndrome Possibly Caused by Molindone Hydrochloride (SR) 1071
Graham, Lynn (author) book review, 1275
Grant, Alexander C. (coauthor) see **Thomson, Alison H.**, 127
Grasela, Thaddeus H., Jr. (author) Clinical and Economic Impact of Oral Ciprofloxacin as Follow-Up to Parenteral Antibiotics (PEP) 857
Grassmick, Bradford K. (coauthor) see **Tutag-Lehr, Victoria**, 25
Grasso, Robert A. (author) Relationship Between Tranylcypromine Sulfate Dose and Monoamine Oxidase Inhibition (L) 99
Gratz, Irwin (coauthor) see **Larijani, Ghassem E.**, 54
Grau, Enric (coauthor) see **Pastor, Emilio**, 1136
Graves, Nina M. (author) Antiepileptic Medications in Development (A) 978
Green, Jeffrey A. (author) The Healthcare Professional of the Future: Function Based upon Competence (O) 205
Green, Paul J. (coauthor) see **Ujhelyi, Michael R.**, 1047
Greenblatt, Ruth M. (coauthor) see **Corelli, Robin L.**, 1374
Gribnau, Frank W. (coauthor) see **Pouwels, Marie-Jose M.**, 1043
Griffin, James H. (author) Lisinopril-Induced Lithium Toxicity (L) 101; (coauthor) see **Hahn, Susan M.**, 1273
Grymonpre, Ruby E. (author) Prescribing Patterns for Older Heavy Drug Users Living in the Community (G) 186
Guba, Elizabeth A. (coauthor) see **Abel, Steven R.**, 348
Gubara, Othman A. (coauthor) see **Bawazir, Saleh A.**, 863
Guglielmo, B. Joseph (coauthor) see **Corelli, Robin L.**, 1374
Guharoy, Sudip Roy (author) Drug Company Influence (L) 1138; (author) Pharm D: All or Some? (L) 679; (author) Streptokinase Versus Recombinant Tissue-Type Plasminogen Activator (L) 1271
Gumbhir, Ashok K. (coauthor) see **Kucukarslan, Suzan N.**, 213
Gums, John G. (coauthor) see **Rey, Aixa M.**, 745
Gundlach, Catherine A. (author) Charge and Reimbursement Analysis for Intensive Care Unit Patients in a Large Tertiary Teaching Hospital (CC) 1231
Guthrie, Sally K. (author) book review, 878; (author) Sertraline: A New Specific Serotonin Reuptake Blocker (FF) 952
Hadsall, Ronald S. (coauthor) see **Black, David R.**, 164
Hahn, Nancy W. (coauthor) see **Whelan, Anne Marie**, 638
Hahn, Susan M. (author) Comment: Fluoxetine Adverse Effects and Drug Interactions (L) 1273; (coauthor) see **Griffin, James H.**, 101
Haley, Christopher J. (coauthor) see **Drees, Christine**, 138
Hamilton, Robert A. (author) book review, 440
Hansen, Charles J. (coauthor) see **Benson, Jill M.**, 272
Hansen, Lea Ann (author) Altretamine (FF) 146
Haramburu, Françoise (author) Authors' Reply: Manual Versus Computer-Based Literature Searches for Adverse Drug Reactions (L) 875; (author) Manual or Computer-Based Literature Searches: Is One Best for Pharmacovigilance? (L) 214
Harding, Godfrey K.M. (coauthor) see **Zhanel, George G.**, 153
Harralson, Arthur F. (coauthor) see **Kehoe, William A.**, 1368
Harris, Jennifer Meyer (author) Correction: Clonidine Patch Toxicity (L) 682
Harrison, Gunyon M. (coauthor) see **Bosso, John A.**, 1168
Hart, Linda L. (author) Correction: Dipyridamole in Angioplasty (L) 1274; (coauthor) see **Brady, Silvia I.**, 1185; (coauthor) see **Lee, Audrey F.**, 361; (coauthor) see **Teruya, Jody L.**, 747; (coauthor) see **Wiehl, Wendy**, 362; (editor) DIAS Rounds, 30, 137, 253, 361, 473, 606, 747, 941, 1076, 1185, 1339
Hartshorn, Edward A. (editor) Drug Interactions and Reactions Update, 191, 657, 1249
Hartzema, Abraham G. (editor) Pharmacoepidemiology, 85, 296, 418, 857, 1113, 1259, 1374
Harvey, John L. (author) Comparative Attitudes to Verbal and Written Medication Information Among Hospital Outpatients (RPR) 925
Hatoum, Hind T. (author) Patient Outcome and the Future Practice of Pharmacy (O) 208
Hatton, Randy C. (author) Comment: Manual Versus Computer-Based Literature Searches for Adverse Drug Reactions (L) 875

Hegman, Greg W. (author) Author's Reply: Ranitidine Does Not Inhibit Theophylline Metabolism (L) 1140; (author) Ranitidine–Theophylline Interaction—Fact or Fiction? (CR) 21
Heidorn, Lisa (author) Dextran Inhibition of Human Immunodeficiency Virus (DIAS) 606
Heller, Allen H. (coauthor) see **Cutler, Neal R.**, 471
Helling, Dennis K. (coauthor) see **Semla, Todd P.**, 410
Hemminki, Elina (author) Use of Estrogens Among Middle-Aged Massachusetts Women (PEP) 418
Hennessy, Sean (author) Gastric Obstruction with Extended-Release Tablets (L) 678
Herfindal, Eric T. (coauthor) see **Day, Robert L.**, 308, 1142
Hetnal, Mieczyslaw J. (coauthor) see **Kehoe, William A.**, 1368
Heyman, Samuel N. (author) Hypertensive Crisis from Chronic Intoxication with Nasal Decongestant and Cough Medications (CR) 1068
Hill, Malcolm R. (author) Pathogenesis of Asthma: Therapeutic Implications (PA) 993
Hilleman, Daniel E. (author) Changing Strategies in the Management of Chronic Congestive Heart Failure (A) 1349; (author) Reducing Time Delays in the Administration of Thrombolytic Therapy to Patients with Acute Myocardial Infarction (A) 1096; (coauthor) see **Malesker, Mark A.**, 231
Hiner, William O., Jr. (coauthor) see **Bjornson, Darrel C.**, 414
Hirschmann, Joseph L. (author) A Brief History of the "DIAS Rounds" (SC) 307
Hitchen, Karen (author) Early Anticoagulation Therapy in Deep Vein Thrombosis (L) 1397
Hoban, Daryl J. (coauthor) see **Zhanel, George G.**, 153
Hobdy-Henderson, Karen C. (coeditor) see **Hart, Linda L.**, 1185, 1339
Hod, Moshe (coauthor) see **Peled, Yoav**, 1181
Hodge, Ernest E. (coauthor) see **Chan, Gary L.**, 211
Hogan, Kathy R. (author) Granulocyte-Macrophage Colony-Stimulating Factor in Neutropenia (DIAS) 32
Hohmann, Ann A. (author) Psychotropic Medication Prescription in US Ambulatory Medical Care (PEP) 85
Hollis, Jack F. (coauthor) see **Johnson, Richard E.**, 730
Hood, Michele A. (author) Fludarabine: A Review (FF) 518
Hooymans, Piet M. (coauthor) see **Pouwels, Marie-Jose M.**, 1043
Hopefl, Alan W. (author) Overview of Synergy with Reference to Double Beta-Lactam Combinations (A) 972
Hosking, Martin C.K. (coauthor) see **Bryson, Scott M.**, 68
Howard, Patricia A. (author) Intravenous Dipyridamole: Use in Thallous Chloride Tl 201 Stress Imaging (FF) 1085; (author) Phenytoin Hypersensitivity Syndrome: A Case Report (CR) 929
Hrehorovich, Victor R. (coauthor) see **Zimmermann, Anthony E.**, 678
Huepenbecker, Dawn (coauthor) see **Grasela, Thaddeus H. Jr.**, 857
Hughes, Roger L. (coauthor) see **Thomson, Alison H.**, 127
Hughes, Thomas E. (coauthor) see **Hansen, Lea Ann**, 146
Hull, Robert Lee (author) Thrombocytopenia Possibly Caused by Structurally Related Third-Generation Cephalosporins (SR) 135
Hume, Anne L. (author) Author's Reply: Lisinopril-Induced Hyponatremia (L) 874; (author) Sources of Influence on the Prescribing Practices of Residents in Family Medicine (L) 102

I-K

Iglesias, A. (coauthor) see **Vidal, C.**, 317
Ignoffo, Robert J. (author) Erythromycin and Cyclosporine Drug Interaction (DIAS) 30
Irwin, Danica B. (coauthor) see **Bryson, Scott M.**, 68
Jacisin, John J. (coauthor) see **Kehoe, William A.**, 1368
Jackson, Debbie (coauthor) see **Peery, Patrick A.**, 1137
Jacobi, Athole G. (coauthor) see **Larijani, Ghassem E.**, 54
Jacobi, Judi (coauthor) see **Dasta, Joseph F.**, 1398
James, Cathe (coauthor) see **Gal, Peter**, 1385
Jameson, John P. (author) Authors' Reply: Aminoglycoside Dosing (L) 1141; (author) The Profession of Pharmacy in Zimbabwe (IR) 302; (author) Three-Point Versus Two-Point Method for Early Individualization of Aminoglycoside Doses (TM) 635
Jankiewicz, Ann M. (author) Ketamine and Succinylcholine for Emergency Intubation of Pediatric Patients (DIAS) 475
Jimenez, M. Monteagudo (coauthor) see **Canals, Antonio Mirada**, 1269
Joe, Ronald H. (coauthor) see **Carter, Charles A.**, 1275
Johnson, Richard E. (author) Patterns of Nicotine Gum Use in a Health Maintenance Organization (RPR) 730
Jones, Mark (author) book review, 322
Jones-Grizzle, Amy J. (author) Economic Analyses in Hypertension: Applications for Healthcare Providers (PEC) 289
Jonville, Annie-Pierre E. (author) Characteristics of Medication Errors in Pediatrics (PEP) 1113
Jørgensen, Jan T. (author) Patient Acceptance of Nordiject: A New Drug Delivery System for Growth Hormone (RPR) 585
Jørgensen, Jens O.L. (coauthor) see **Jorgensen, Jan T.**, 585
Jungnickel, Paul W. (author) Comment: Adverse-Effect Profile of Sustained-Release Niacin (L) 1014
Kadmon, Dov (coauthor) see **Moss, Jeffrey T.**, 1355
Kahana, Leo M. (author) Ciprofloxacin in Patients with Mycobacterial Infections: Experience in 15 Patients (RPR) 919
Kamada, Alan K. (coauthor) see **Hill, Malcolm R.**, 993
Kamper, Claudia (coauthor) see **Sagraves, Rosalie**, 760
Kandrotas, Robert J. (coauthor) see **Benson, Jill M.**, 272
Kapusnik-Uner, Joan E. (coauthor) see **Corelli, Robin L.**, 1374
Karboski, James A. (coauthor) see **Godley, Paul J.**, 179
Karp, Richard A. (coauthor) see **Edelstein, Howard E.**, 914
Kasilo, Ossy J. (author) Recommendations for Establishing a Drug and Toxicology Information Center in a Developing Country (IR) 1379; (coauthor) see **Jameson, John P.**, 302
Kassen, Barry O. (coauthor) see **Levine, Marc**, 743
Kato, Motoichi (coauthor) see **Ueno, Kazuyuki**, 727
Katona, Brian G. (coauthor) see **Zimmermann, Anthony E.**, 678
Katz, Gail M. (coauthor) see **McKenney, James M.**, 234
Kaufman, Kimberly (coauthor) see **Brady, Silvia I.**, 1185
Kawaguchi, Yoshihiro (coauthor) see **Ueno, Kazuyuki**, 727
Kawashima, Syuichi (coauthor) see **Ueno, Kazuyuki**, 317
Kehoe, William A. (author) Early Individualization of Tricyclic Antidepressant Dosing Using a Bayesian Pharmacokinetic Model (TM) 1368
Kelly, H. William (author) Asthma, Aerosols, and Patient Education (E) 668; (author) Comment: Ranitidine Does Not Inhibit Theophylline Metabolism (L) 1139; (author) Corticosteroids for Acute, Severe Asthma (PA) 72; (coeditor) see **Milavetz, Gary**, 72, 638, 993
Keys, Patricia A. (author) Therapeutic Strategies for Myasthenia Gravis (A) 1101
Khalil, Shoukry K.W. (coauthor) see **Miller, Donald R.**, 1302
Kim, Laura E. (coauthor) see **Ignoffo, Robert J.**, 30
King, Todd (author) Brachial Plexus Palsy with the Use of Haloperidol and a Geriatric Chair (SR) 1072
Kirking, Duane M. (author) Authors' Reply: Parenteral H$_2$-Receptor Antagonist Intervention (L) 682; (author) Evaluation of Direct Pharmacist Intervention on Conversion from Parenteral to Oral Histamine H$_2$-Receptor Antagonist Therapy (PEC) 80
Knapp, Teresa R.F. (author) Adverse Effects of Sustained-Release Niacin (DIAS) 253; (author) Comment: Adverse-Effect Profile of Sustained-Release Niacin (DIAS) 1014
Koeller, Jim M. (coauthor) see **Fields, Suzanne M.**, 505
Kohler, David R. (author) Ondansetron: A Serotonin-Receptor (5-HT$_3$) Antagonist for Antineoplastic Chemotherapy-Induced Nausea and Vomiting (FF) 367; (coauthor) see **Goldspiel, Barry R.**, 796
Kohli-Kumar, Mudra (author) Urinary Retention—An Unusual Dystonic Reaction to Continuous Metoclopramide Infusion (SR) 469
Koks, Cees H.W. (coauthor) see **Beijnen, Jos H.**, 869
Konichezky, Sergio (coauthor) see **Shapira, Oz M.**, 354
Korek, Joan S. (coauthor) see **Cantú, Thomas G.**, 1079
Krause, John R. (coauthor) see **Vanscoy, Gordon J.**, 1190
Krop, Lynne C. (author) Drug-Induced Systemic Lupus Erythematosus (L) 212
Kucukarslan, Suzan N. (author) Evaluation of Concomitant Drug Use During Antidepressant Therapy (L) 213
Kuroki, Yasuo (coauthor) see **Shiozawa, Shunichi**, 101
Kurtz, Neil M. (coauthor) see **Cutler, Neal R.**, 471
Kwentus, Joseph A. (coauthor) see **Kehoe, William A.**, 1368

L-M

Lacombe, Sylvia (author) Pharmacologic Treatment of Cocaine Abuse (A) 818
Lamott, Jo Anna (coauthor) see **Colbert, James Jr.**, 559
Lamp, Kenneth C. (author) Indomethacin for Prevention of Neonatal Intraventricular Hemorrhage (TC) 1344
Landau, Zvi (coauthor) see **Malnick, Stephen D.H.**, 869
Lang, Ruth (coauthor) see **Elis, Avishay**, 461
Larijani, Ghassem E. (author) Clinical Pharmacology of the Neuromuscular Blocking Agents (A) 54
Larson, David B. (coauthor) see **Hohmann, Ann A.**, 85
Lavarenne, J. (coauthor) see **Souweine, B.**, 1137
Lawson, Lisa A. (coauthor) see **Munar, Myrna Y.**, 1306
LeBel, Marc (coauthor) see **Parent, Marc**, 191
Lechner, Judith L. (coauthor) see **Stumpf, Janice L.**, 239
Lee, Ai Young (author) Provocation Tests in a Chlormezanone-Induced Fixed Drug Eruption (SR) 604
Lee, Audrey F. (author) Verapamil in Premenstrual Syndrome (DIAS) 361
Lee, Connie R. (author) Pegademase Bovine: Replacement Therapy for Severe Combined Immunodeficiency Disease (FF) 1092
Lee, Sophia H. (author) Vitamin D in Psoriasis (DIAS) 753
Lee, Yoo Shin (coauthor) see **Lee, Ai Young**, 604
Lehany, Anne Marie (coauthor) see **Weksler, Babette B.**, 1183
Lemke, Jon H. (coauthor) see **Semla, Todd P.**, 410
Lener, Michelle E. (coauthor) see **Watson, William A.**, 463
Leo, Raphael J. (author) Seizure Activity Associated with Imipenem Use: Clinical Case Reports and Review of the Literature (CR) 351
Leppik, Ilo E. (coauthor) see **Graves, Nina M.**, 978
Lesar, Timothy S. (coauthor) see **Vitillo, Josephine A.**, 1388
Leson, Cheryl L. (coauthor) see **Bryson, Scott M.**, 68
Levine, Marc (author) Acute Hemolysis and Renal Failure Following Discontinuous Use of Rifampin (SR) 743
Levine, Steven R. (coauthor) see **Fagan, Susan C.**, 1299
Levinson, Miriam L. (author) Adverse Effects and Drug Interactions Associated with Fluoxetine Therapy (DIR) 657
Levy, Gerhard (author) The Pharm.D.: All or Some? (SC) 94
Lewis, John A. (coauthor) see **Jameson, John P.**, 635, 1141
Liedholm, Hans (author) Erythromycin–Felodipine Interaction (L) 1007
Ligumsky, Moshe (coauthor) see **Oren, Ran**, 315
Lin, Anne Y. (coauthor) see **Etzel, Joseph V.**, 1341
Linares, Mariano (coauthor) see **Pastor, Emilio**, 1136
Lindsay, Christine A. (author) book review, 104
Lipsy, Robert J. (coauthor) see **Levinson, Miriam L.**, 657
Liptak, Carolyn A. (coauthor) see **Bosso, John A.**, 1168
Lishner, Michael (coauthor) see **Elis, Avishay**, 461
Lisi, Donna M. (author) Comment: Legal Duty to Counsel (L) 1274
Littlewood, Alison M. (coauthor) see **Batty, Kevin T.**, 1138
Livshitz, Tatyana (coauthor) see **Oren, Ran**, 315
Lleonart-Bellfill, Ramon (author) Tetanus Toxoid Anaphylaxis (L) 870
Lomaestro, Ben M. (author) Quinolone–Cation Interactions: A Review (DIR) 1249
Lopez, Larry M. (coauthor) see **Sproat, Thomas T.**, 962; (coauthor) see **Yedinak, Kimberly C.**, 1193
Loughead, Teri A. (coauthor) see **Black, David R.**, 164
Loughner, John E. (author) Comment: Plicamycin Infusion (L) 215
Love, John H. (coauthor) see **Van Slooten, Andrea D.**, 578
Luther, R. Wayne (coauthor) see **Broyles, Joyce E.**, 119
Lynch, Thomas E. (coauthor) see **Cutler, Neal R.**, 471
Lysy, Joseph (coauthor) see **Oren, Ran**, 315
MacDonald, Joanne L. (coauthor) see **Mauro, Vincent F.**, 257
Mahoney, Janelle M. (author) Comment: Subtherapeutic Drug Concentrations and Compliance (L) 1016
Malesker, Mark A. (author) Pharmacokinetic and Tolerance Evaluation of Actisomide, a New Antiarrhythmic Agent, in Healthy Volunteers (RPR) 231
Mallet, Louise (author) Tuberculosis in the Elderly: Incidence, Manifestations, PPD Skin Tests, and Preventive Therapy (G) 650; (coauthor) see **King, Todd**, 1072
Malnick, Stephen D.H. (author) Bezafibrate-Induced Rhabdomyolysis (L) 869
Maloley, Pierre A. (coauthor) see **Jungnickel, Paul W.**, 1014
Mandler, Hilary D. (author) book review, 1401
Marcheix, Jean-Claude (coauthor) see **Aumaitre, Olivier**, 1136
Marikis, Bessie (coauthor) see **Baumann, Terry J.**, 724
Marken, Patricia A. (coauthor) see **Lacombe, Sylvia**, 818
Marroni, Massimo (author) Accidental Intravenous Infusion of Sodium Hypochlorite (L) 1008
Marroum, Patrick J. (coauthor) see **Curry, Monica L.**, 437
Marsh, T. Donald (coauthor) see **Fitzgerald, Jill Mancini**, 140, 1015
Marten, Julianna T. (coauthor) see **Brusko, Cynthia S.**, 1321
Martin, Susan E. (coauthor) see **Smythe, Maureen A.**, 1058
Martinez-Abad, Manuel (author) Vitamin K$_1$ and Anaphylactic Shock (L) 871
Martucci, Joel D. (author) book review, 106
Mascioli, Edward A. (coauthor) see **Driscoll, David F.**, 276
Mason, Barbara J. (author) Subtherapeutic Serum Drug Concentrations and Compliance (L) 103
Matsumoto, Katsuyoshi (coauthor) see **Ueno, Kazuyuki**, 317
Mattox, Todd W. (author) Overview of Biochemical Markers Used for Nutrition Support (A) 265
Mauro, Vincent F. (author) book review, 684; (author) Simvastatin: A Review of Its Pharmacology and Clinical Use (FF) 257
May, Franklin E. (author) book review, 105
Mayo, Maureen (author) Calcium Carbonate in Hyperphosphatemia (DIAS) 945
McAskill, A. Cheryl (coauthor) see **Olson, Lisa A.**, 100
McCabe, Robert E. (coauthor) see **Edelstein, Howard E.**, 914, 1007
McCollam, Patrick L. (coauthor) see **Schneider, Philip J.**, 1269
McCullough, Jill M. (author) Oral Vancomycin-Induced Rash: Case Report and Review of the Literature, 1326
McGhan, William F. (editor) Pharmacoeconomics, 80, 289, 414, 546
McGrath, Betty J. (author) Adenosine in Supraventricular Tachycardia (DIAS) 749; (author) Fluoxetine and Suicidal Ideation (DIAS) 607
McKenney, James M. (author) The Effect of Phenylpropanolamine on 24-Hour Blood Pressure in Normotensive Subjects Administered Indomethacin (RPR) 234; (coauthor) see **Sesler, Jefferson M.**, 1310
McKenzie, Constance A. (coauthor) see **Lee, Connie R.**, 1092; (coauthor) see **Rumbaugh, Marsha M.**, 1144
McKinlay, Sonja M. (coauthor) see **Hemminki, Elina**, 418
McKinney, Patrick E. (coauthor) see **Watson, William A.**, 1081
McMaster, James R. (coauthor) see Corelli, Robin L., 1374
McNulty, Claudia J. (coauthor) see **Bright, Thomas P.**, 1066
McQueen, Kellie D. (coauthor) see **Artoux, Michelle J.**, 363; (coauthor) see **Lee, Sophia H.**, 753; (coauthor) see **Neff, David A.**, 31; (coauthor) see **Taylor, Mark D.**, 1076; (coauthor) see Wong, Laura, 476
Menichetti, Francesco (coauthor) see **Marroni, Massimo**, 1008
Merlob, Paul (coauthor) see **Ben-Amitai, Dan**, 1009; (coauthor) see **Peled, Yoav**, 1181

Mevorach, Dror (coauthor) see **Heyman, Samuel N.**, 1068
Michaud, Roger (coauthor) see **Sesin, G. Paul,** 1011
Middleton, Robert K. (coauthor) see **Brady, Silvia I.,** 1077; (coauthor) see **Choy, Melissa,** 609; (coauthor) see **Franson, Kari L.,** 750; (coauthor) see **Knapp, Teresa R.F.,** 253, 1014; (coauthor) see **Mayo, Maureen,** 945; (coauthor) see **Nguyen, Trang,** 254; (coauthor) see **Toy, Connie,** 1340; (coauthor) see **Yao, Lillian J.,** 1187; (coeditor) see **Hart, Linda L.,** 30, 137, 253, 361, 473, 606, 747, 941, 1076
Mignott, Harold (coauthor) see **Hennessy, Sean,** 678
Milavetz, Gary (editor) Pulmonary and Allergy, 72, 638, 993
Milburn, Diane S. (author) Tryptophan Toxicity: A Pharmacoepidemiologic Review of Eosinophilia–Myalgia Syndrome (PEP) 1259
Military Medical Consortium for Applied Retroviral Research, see **Bjornson, Darrel C.,** 414
Miller, Donald R. (author) Steady-State Pharmacokinetics of Hydroxychloroquine in Rheumatoid Arthritis Patients (RPR) 1302; (coauthor) see **Olson, Lisa A.,** 100
Miller, Douglas A. (coauthor) see **Tisdale, James E.,** 680
Minor, James R. (author) Foscarnet Sodium (FF) 41
Minton, Stephen D. (coauthor) see **Reed, Michael D.,** 344
Mitenko, Paul A. (coauthor) see **Grymonpre, Ruby E.,** 186
Mitrano, Francis P. (coauthor) see **Driscoll, David F.,** 276
Mitsuzane, Kiyoshi (coauthor) see **Ueno, Kazuyuki,** 1273
Miya, Tom S. (author) Progress and Problems: A Personal Perspective (RC) 1133
Miyahara, Randell K. (coauthor) see **Stajich, Gregory V.,** 14
Miyai, Kazuyoshi (coauthor) see **Ueno, Kazuyuki,** 317, 727, 1273
Miyakawa, Kaoru (coauthor) see **Shindo, Kunihiko,** 1009
Mizuno, Tadaoki (coauthor) see **Shindo, Kunihiko,** 1009
Mohindra, Subodh K. (author) Intravenous Esmolol in Acute Aortic Dissection (CR) 735
Mohiuddin, Syed M. (coauthor) see **Hilleman, Daniel E.,** 1349; (coauthor) see **Malesker, Mark A.,** 231
Mojaverian, Parviz (author) book review, 216
Montgomery, Patrick R. (coauthor) see **Grymonpre, Ruby E.,** 186
Moore, Emory S. (coauthor) see **Godley, Paul J.,** 179
Mor, Eitan (coauthor) see **Shapira, Oz M.,** 354
Morales-Olivas, Francisco J. (coauthor) see **Martinez-Abad, Manuel,** 871
Morimoto, Ippei (coauthor) see **Shiozawa, Shunichi,** 101
Mortensen, Henrik B. (coauthor) see **Jorgensen, Jan T.,** 585
Morton, Mark R. (author) Delirium in an Elderly Woman Possibly Associated with Administration of Misoprostol (SR) 133
Moss, Jeffrey T. (author) BCG and the Treatment of Superficial Bladder Cancer (A) 1355
Mummaw, Nancy (coauthor) see **Stein, Gary E.,** 582
Munar, Myrna Y. (author) Gentamicin Pharmacokinetics in Postpartum Women with Endomyometritis (RPR) 1306
Munger, Mark A. (coauthor) see **Gardner, Stephanie F.,** 1336
Munroe, Wendy P. (coauthor) see **Sesler, Jefferson M.,** 1310
Murphy, Shirley (coauthor) see **Kelly, H. William,** 72
Muscettola, Giovanni (author) Pattern of Neuroleptic Drug Use in Italian Mental Health Services (PEP) 296
Myers, Carol W. (coauthor) see **Milburn, Diane S.,** 1259

N-O

Nacci, Nancy (coauthor) see **Fagan, Susan C.,** 247
Nafria, Esteve Colomé (author) Renal Papillary Necrosis Induced by Flurbiprofen (L) 870
Nahata, Milap C. (author) Emergency Healthcare in India (IR) 424; (author) Research Productivity and Funding (E) 669; (author) Stability of Ceftriaxone Sodium in Peritoneal Dialysis Solutions (SR) 741; (author) Stability of Labetalol Hydrochloride in Distilled Water, Simple Syrup, and Three Fruit Juices (SR) 465; (coauthor) see **Bahal, Neeta,** 542; (coauthor) see **Powell, Dwight A.,** 1236
Nakata, Izumi (coauthor) see **Ueno, Kazuyuki,** 317
Nathan, Cecelia (coauthor) see **Cool-Foley, Alicia A.,** 1331
Natowicz, Marvin (author) Digoxin Assay Anomalies Due to Digoxin-Specific Fab Immunotherapy (SR) 739
Neff, David A. (author) Beta-Blockers in Alcohol Withdrawal (DIAS) 31
Nelson, E. Don (author) book review, 322
Newman, William P. (coauthor) see **Olson, Lisa A.,** 100
Nguyen, Trang (author) Fluoxetine in Bulimia (DIAS) 254
Nhachi, Charles F.B. (coauthor) see **Kasilo, Ossy J., 1379**
Nickel, Ronald O. (coauthor) see **Shaughnessy, Allen F.,** 17
Nickman, Nancy A. (author) book review, 1144; (coauthor) see **Galinsky, Raymond E.,** 431
Nicolau, David P. (author) Comment: Lisinopril-Induced Hyponatremia (L) 873
Nightingale, Charles H. (coauthor) see **Briceland, Laurie L.,** 319
Nix, David E. (coauthor) see **Dolgin, Jill G.,** 646; (coauthor) see **Schentag, Jerome J.,** 1050; (coauthor) see **Van Slooten, Andrea D.,** 578
Nolly, Robert J. (coauthor) see **Broyles, Joyce E.,** 119
Nordin, Gunnar (coauthor) see **Liedholm, Hans,** 1007
Norris, Sandra (coauthor) see **Sirgo, Mark A.,** 284
Nowakowski, Phillip (coauthor) see **Jankiewicz, Ann M.,** 475
Nygard, Gloria A. (coauthor) see **Miller, Donald R.,** 1302
O'Donovan, Charles III (coauthor) see **Cool-Foley, Alicia A.,** 1331
Ogbuokiri, Justine E. (author) Comment: Pharm.D.: All or Some? (L) 1400
Oh, Taeho (coauthor) see **Hitchen, Karen ,** 1398
O'Keeffe, Shaun (author) Comment: Potassium Supplements vs. Potassium-Sparing Diuretics (L) 439
Olek, Chris (coauthor) see **Loughner, John E.,** 215
Olivé-Perez, Alfonso (coauthor) see **Lleonart-Bellfill, Ramon,** 870
Olsen, Keith M. (author) E5 Monoclonal Immunoglobulin M Antibody for the Treatment of Gram-Negative Sepsis (FF) 784; (coauthor) see **Ackerman, Bruce H.,** 867
Olson, Carol H. (coauthor) see **Van Dyke, Don C.,** 987
Olson, Lisa A. (author) Inadvertent Administration of Acetohexamide Instead of Acetazolamide (L) 100
O'Quinn, Stephen V. (author) Nitrate Tolerance: Does TID Isosorbide Dinitrate Mean Dosing Every Eight Hours? (L) 1272
Oren, Ran (author) Pentoxifylline-Induced Gastrointestinal Bleeding (L) 315
Orlando, Patricia L. (author) book review, 560
Ornato, Joseph P. (coauthor) see **Gonzalez, Edgar R.,** 773
Osborn, John J. (coauthor) see **Schneider, Philip J.,** 1269
Osborne, Robert C. (coauthor) see **Raisch, Dennis W.,** 716
Ossi, Michael J. (coauthor) see **Powell, Dwight A.,** 1236
Oster, Charles N. (coauthor) see **Bjornson, Darrel C.,** 414
Oster, Sharon E. (coauthor) see **Edelstein, Howard E.,** 914
Outman, William R. (coauthor) see **Briceland, Laurie L.,** 319

P-R

Paladino, Joseph A. (coauthor) see **Grasela, Thaddeus H. Jr.,** 857
Palop, Vicente (coauthor) see **Martinez-Abad, Manuel,** 871
Pampallona, Sandro (coauthor) see **Muscettola, Giovanni,** 296
Pappas, Alexandros A. (coauthor) see **Ackerman, Bruce H.,** 867
Parent, Marc (author) Meta-Analysis of Quinolone–Theophylline Interactions (DIR) 191
Parish, Roy (author) book review, 1017
Pastor, Emilio (author) Erythromycin-Induced Agranulocytosis (L) 1136
Pearson, Andrew D.J. (coauthor) see **Kohli-Kumar, Mudra,** 469
Peery, Deborah (coauthor) see **McCullough, Jill M.,** 1326
Peery, Patrick A. (author) Meperidine-Induced Taste Alteration (L) 1137
Peled, Yoav (author) Ofloxacin During the Second Trimester of Pregnancy (SR) 1181
Perry, Paul J. (author) Switching Haloperidol from Oral to IM Depot Formulation (L) 1270; (author) Triazolam—The Never-Ending Story (E) 1263; (coauthor) see **Grasso, Robert A.,** 99
Peters, Mark D., II (coauthor) see **Hogan, Kathy R.,** 32
Peterson, Andrew M. (author) Procainamide-Induced Pseudo-Obstruction in a Diabetic Patient (SR) 1334
Peterson, John (coauthor) see **Rivey, Michael P.,** 628
Philippe, P. (coauthor) see **Souweine, B.,** 1137
Pinkhas, Jack (coauthor) see **Pras, Elon,** 939
Pleasants, Roy A. (coauthor) see **Williams, Dennis M.,** 1140
Plumridge, Richard J. (coauthor) see **Harvey, John L.,** 925
Ponte, Charles D. (author) Digoxin—Farewell, Old Friend or Un-*Squill* We Meet Again! (L) 320; (author) Inadvertent Intravenous Administration of Methylprednisolone Acetate in a Child (L) 436
Porta, Miquel S. (coeditor) see **Hartzema, Abraham G.,** 85, 296, 418, 857, 1113, 1259, 1374
Posner, Jennifer G. (coauthor) see **Hemminki, Elina,** 418
Pouwels, Marie-José M. (author) Comparison of Steady-State Serum Concentrations of Digoxin in Tablets (Lanoxin) and Capsules (Lanoxicaps) in the Elderly (RPR) 1043
Powell, Dwight A. (author) The Safety, Efficacy, and Tolerability of Cefuroxime Axetil Suspension in Infants and Children Receiving Previous Intravenous Antibiotic Therapy (PED) 1236
Powell, Nancy E. (coauthor) see **Powell, Dwight A.,** 1236
Pras, Elon (author) Urinary Retention Associated with Ipratropium Bromide (SR) 939
Purcell, Jeffrey B. (coauthor) see **Grasela, Thaddeus H. Jr.,** 857
Quintiliani, Richard (coauthor) see **Briceland, Laurie L.,** 319
Raasch, Ralph H. (author) Pravastatin Sodium, A New HMG-CoA Reductase Inhibitor (FF) 388
Rae, Charlesworth E. (author) Successful Treatment of Neonatal *Citrobacter freundii* Meningitis with Ceftriaxone (SR) 27; (author) Ten Cases of Acute Lead Intoxication Among Bridge Workers in Louisiana (CR) 932
Raebel, Marsha A. (coeditor) see **Thompson, Dennis F.,** 478, 613, 760, 773, 948, 1081, 1190
Raisch, Dennis W. (author) Evaluation of a Non-Food and Drug Administration-Approved Use of Cimetidine: Treatment of Pruritus Resulting from Epidural Morphine Analgesia (RPR) 716
Ramadan, Nabih M. (coauthor) see **Fagan, Susan C.,** 1299
Ramos-Caro, Francisco A. (coauthor) see **Goodless, Dean R.,** 395
Ransom, J. Laurence (coauthor) see **Gal, Peter,** 853
Ravid, Mordchai (coauthor) see **Elis, Avishay,** 461
Raymond, Glynn G. (author) Physical Compatibility and Chemical Stability of Amphotericin B in Combination with Magnesium Sulfate in 5% Dextrose Injection (RPR) 123
Reed, Michael D. (author) Ceftizoxime Disposition in Neonates and Infants During the First Six Months of Life (RPR) 344; (author) Editor's Reply: We Use Drugs Too—More Pediatric Information in Review Articles (L) 559; (coauthor) see **Gal, Peter,** 1385; (coauthor) see **Usala, Anton-Lewis,** 1384; (editor) Pediatrics, 68, 179, 272, 408, 542, 646, 853, 987, 1109, 1236
Reichley, Richard (coauthor) see **Mahoney, Janelle M.,** 1016
Rey, Aixa M. (author) Altered Absorption of Digoxin, Sustained-Release Quinidine, and Warfarin with Sucralfate Administration (SR) 745
Reynolds, Maryann S. (coauthor) see **Lamp, Kenneth C.,** 1344
Rihn, Thomas L. (coauthor) see **Bero, Christopher J.,** 1329; **Shovick, Virginia A.,** 598
Rindone, Joseph P. (author) Author's Reply: Attribution of Blame in Drug-Induced Thrombocytopenia (L) 875
Ritchie, David J. (author) Comment: Consideration of Amphotericin B Hepatotoxicity (L) 559
Rivey, Michael P. (author) Intradermal Hepatitis B Vaccination (A) 628
Robbins, Marshall E. (coauthor) see **Morton, Mark R.,** 133
Robert, Sylvie (author) Is There a Reliable Index of Glomerular Filtration Rate in Critically Ill Patients? (CC) 169; (coauthor) see **Ujhelyi, Michael R.,** 1047
Robinson, Dennis H. (author) book review, 323
Robinson, J. Daniel (editor) Therapeutic Monitoring, 635, 1368
Rodger, R. Stuart C. (coauthor) see **Thomson, Alison H.,** 127
Rodriguez, M. (coauthor) see **Vidal, C.,** 317
Rodriguez Moreno, Carlos (coauthor) see **Canals, Antonio Mirada,** 1269
Rodvold, Keith A. (coauthor) see **Erdman, Sharon M.,** 941; (coauthor) see **Shwed, Jill A.,** 10
Rosales, Joaquin P. (coauthor) see **Rae, Charlesworth E.,** 27
Rosique, Dolores (coauthor) see **Sanchis, Amparo,** 1137
Rothbart, David (author) Comment: Mesalamine in Ulcerative Colitis (L) 1015
Roush, Maura Kraynak (author) Significance of the Ciprofloxacin–Antacid Interaction (DIAS) 473
Rue, Peter J. (author) Volmax: Simulated Gastrointestinal pH and Agitation Studies (L) 438
Ruivard, M. (coauthor) see **Souweine, B.,** 1137
Rumbaugh, Marsha M. (author) book review, 1144
Rumsfield, Jean A. (author) Topical Capsaicin in Dermatologic and Peripheral Pain Disorders (FF) 381
Rutledge, David R. (author) Are There Beta-Adrenergic Receptor Response Differences Between Racial Groups? (A) 824; (author) Effect of Age on Lymphocyte Beta$_2$-Adrenergic Responsiveness (A) 532
Ryan, Michael L. (coauthor) see **Kirking, Duane M.,** 80, 682; (coauthor) see **Stumpf, Janice L.,** 239
Rybacki, James (coauthor) see **Grasela, Thaddeus H. Jr.,** 857
Rybak, Michael J. (coauthor) see **Albrecht, Lisa M.,** 713

S-T

Sacristán, José Antonio (coauthor) see **Alvarez, Javier Soto,** 558, 1397
Sáez, A. (coauthor) see **Vidal, C.,** 317
Sagraves, Rosalie (author) Controversies in Cardiopulmonary Resuscitation: Pediatric Considerations (TC) 760; (coauthor) see **Godley, Paul J.,** 179
Sailstad, Jeffrey M. (coauthor) see **Allen, Nancy M.,** 1315
Samuels, Philip (coauthor) see **Munar, Myrna Y.,** 1306
Sanchez, Javier (coauthor) see **Dolgin, Jill G.,** 646
Sanchis, Amparo (author) Adverse Effects of Maternal Lorazepam on Neonates (L) 1137
Sands, Mark F. (coauthor) see **Watson, William A.,** 463
Santos, Jose Ignacio (coauthor) see **Reed, Michael D.,** 344
Sarrut, Bernard (coauthor) see **Biarez, Odile,** 1062
Savir, Hanna (coauthor) see **Avisar, Rahamim,** 359
Sawin, Suzanne (coauthor) see **Cutler, Neal R.,** 471
Sayler, Debra J. (author) Possible Procainamide-Induced Myopathy (L) 436
Schad, Randy F. (coauthor) see **Smythe, Maureen A.,** 1058
Schattner, Ami (author) Colchicine to Prevent Halothane Hepatitis? (L) 211
Schatz, Beth S. (coauthor) see **Bressler, Linda R.,** 1225
Schentag, Jerome J. (author) Mathematical Examination of Dual Individualization Principles (I): Relationships Between AUC Above MIC and Area Under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin (RPR) 1050; (coauthor) see **Grasela, Thaddeus H. Jr.,** 857
Schlech, Walter F., III (coauthor) see **Dugandzic, Rose M.,** 316
Schlicht, John R. (author) Confusing Bacterial Endocarditis Recommendations (L) 1396
Schneider, Philip J. (author) Possible Dissociation of the Digibind–Digoxin Complex in Renal Failure (L) 1269

Schott, Anne Marie (author) Flutamide-Induced Methemoglobinemia (SR) 600
Schulman, Kevin A. (coauthor) see **Hennessy, Sean,** 678
Seilheimer, Dan K. (coauthor) see **Bosso, John A.,** 1168
Self, Timothy H. (author) Comment: Metered-Dose Inhalers (L) 321
Semla, Todd P. (author) Perceived Purpose of Prescription Drugs: The Iowa 65+ Rural Health Study (G) 410
Sen, Sandip (coauthor) see **Stanislav, Steven W.,** 1396
Sesin, G. Paul (author) Ceftriaxone Drug Utilization Evaluation in a Large Community Hospital (L) 872; (author) Computer Monitoring Ciprofloxacin–Theophylline Interactions (L) 1011; (author) Imipenem/Cilastatin Drug Utilization Evaluation in a Large Community Hospital (L) 1399
Sesler, Jefferson M. (author) Clinical Evaluation of a Finger Oscillometric Blood Pressure Device (RPR) 1310
Shalev, Oded (author) Long-Term, Low-Dose Aspirin Is Safe in Glucose-6-Phosphate Dehydrogenase Deficiency (SR) 1074
Shannon, Michael (coauthor) see **Rae, Charlesworth E.,** 932
Shapira, Oz M. (author) Impaired Water Homeostasis Following Mixed Carbamazepine and Phenobarbital Overdose (CR) 354
Sharkey, Ian (coauthor) see **Kohli-Kumar, Mudra,** 469
Shaughnessy, Allen F. (author) Improving Prescription-Writing Skills in a Family Practice Residency (RPR) 17; (coauthor) see **Hume, Anne L.,** 102
Shaw, Leslie (coauthor) see **Natowicz, Marvin,** 739
Shea, Brian F. (author) book review, 216
Sheffel, William B. (coauthor) see **Kehoe, William A.,** 1368
Sherman, Arnold D. (coauthor) see **Grasso, Robert A.,** 99
Shindo, Kunihiko (author) Hepatocellular Carcinoma Response to Low-Dose Oral Tegafur (L) 1009
Shiozawa, Shunichi (author) Schizophyllan Augments Development of Immunoglobulin-Secreting Cells upon Costimulation with *Staphylococcus aureus* Cowan I (L) 101
Shovick, Virginia A. (author) Decreased Hypoprothrombinemic Response to Warfarin Secondary to the Warfarin–Nafcillin Interaction (CR) 598
Shwed, Jill A. (author) A Comparative Evaluation of the Safety and Efficacy of Cefotetan and Cefoxitin in Surgical Prophylaxis (RPR) 10
Sidi, Yechezkel (coauthor) see **Pras, Elon,** 939
Silverberg, Michael (coauthor) see **Larijani, Ghassem E.,** 54
Simon, Deborah (coauthor) see **Cool-Foley, Alicia A.,** 1331
Sirgo, Mark A. (author) Ceftazidime in the Elderly: Appropriateness of Twice-Daily Dosing (G) 284
Sitar, Daniel S. (coauthor) see **Grymonpre, Ruby E.,** 186; (coauthor) see **Strong, Dawn K.,** 1175
Sketch, Michael H., Sr. (coauthor) see **Malesker, Mark A.,** 231
Sketris, Ingrida S. (coauthor) see **Dugandzic, Rose M.,** 316
Skoutakis, Vasilios A. (coauthor) see **Carter, Charles A.,** 1275
Slaughter, Richard L. (coauthor) see **Tisdale, James E.,** 680; (coauthor) see **Touchette, Mark A.,** 1214
Smith, Daniel A. (coauthor) see **Perry, Paul J.,** 1263
Smith, Thomas A., II (author) Chemical Peritonitis Associated with Intraperitoneal Vancomycin (SR) 602
Smith, Valorie H. (coauthor) see **Carter, Charles A.,** 1275
Smythe, Maureen A. (author) Retrospective Evaluation of Patient-Controlled Analgesia Use in a Large Teaching Institution (RPR) 1058; (coauthor) see **Baumann, Terry J.,** 724
Solans, Roser (coauthor) see **Nafria, Esteve Colomé,** 870
Solimando, Dominic A., Jr. (author) book review, 1144
Sommi, Roger W. (coauthor) see **Stanislav, Steven W.,** 1396
Sorby, Donald L. (coauthor) see **Day, Robert L.,** 308, 1142
Souweine, B. (author) Acute Pancreatitis Associated with Roxithromycin Therapy (L) 1137
Spino, Michael (coauthor) see **Kahana, Leo M.,** 919
Spivey, J. Michael (coauthor) see **Van Slooten, Andrea D.,** 578
Sproat, Thomas T. (author) Around the Beta-Blockers, One More Time (DSP) 962
Sramek, John J., Jr. (coauthor) see **Cutler, Neal R.,** 471
Stablien, Amy M. (coauthor) see **Schlicht, John R.,** 1396
Stajich, Gregory V. (author) In Vitro Evaluation of Bleomycin-Induced Cell Lethality from Plastic and Glass Containers (RPR) 14
Stanek, Eric J. (coauthor) see **Gardner, Stephanie F.,** 1336
Stanislav, Steven W. (author) Fluoxetine-Induced Mania in a Suicidal Depressed Patient (L) 1395; (coauthor) see **Lacombe, Sylvia,** 818
Stein, Gary E. (author) Comparative Study of Fluconazole and Clotrimazole in the Treatment of Vulvovaginal Candidiasis (RPR) 582
Steinberg, Joel D. (coauthor) see **Rutledge, David R.,** 532
Stevens, Victor J. (coauthor) see **Johnson, Richard E.,** 730
Stewart, Ronald B. (editor) Geriatrics and Gerontology, 186, 284, 410, 650
Stienlauf, Shmuel (coauthor) see **Pras, Elon,** 939
Stock, Christopher J. (author) Safe Use of Codeine in the Recovering Alcoholic or Addict (A) 49
Stoukides, Cheryl A. (coauthor) see **McGrath, Betty J.,** 607, 749
Stoysich, Anne (coauthor) see **Malesker, Mark A.,** 231
Strong, Dawn K. (author) Amantadine Neurotoxicity in a Pediatric Patient with Renal Insufficiency (CR) 1175
Strozyk, William R. (coauthor) see **Mallet, Louise,** 650
Stumpf, Janice L. (author) Use of Albumin in a University Hospital: The Value of Targeted Physician Intervention (RPR) 239
Supernaw, Robert B. (author) book review, 439
Suzuki, Toshio (coauthor) see **Ueno, Kazuyuki,** 727
Svinte, Michelle K. (coauthor) see **Kirking, Duane M.,** 80, 682
Swanson, Keith A. (author) book review, 1402
Tanaka, Yasushi (coauthor) see **Shiozawa, Shunichi,** 101
Tanaka-Kido, Jorge (coauthor) see **Reed, Miçhael D.,** 344
Tarao, Kazuo (coauthor) see **Shindo, Kunihiko,** 1009
Taylor, David M. (author) Variable Theophylline Clearance in Cystic Fibrosis (L) 212
Taylor, Mark D. (author) Verapamil as Migraine Prophylaxis (DIAS) 1076
Teasley, Kathleen M. (coauthor) see **Mattox, Todd W.,** 265
Teller, Jacob (coauthor) see **Avisar, Rahamim,** 359
Teruya, Jody L. (author) Dipyridamole in Angioplasty (DIAS) 747
Thompson, Dennis F. (author) Correction: Nafarelin Figure Credit Omitted (L) 321; (coauthor) see **Eselin, Julie,** 1187; (editor) Therapeutic Controversies, 478, 613, 760, 773, 948, 1081, 1190
Thompson, James W. (coauthor) see **Hohmann, Ann A.,** 85
Thomson, Alison H. (author) Gentamicin and Vancomycin Removal by Continuous Venovenous Hemofiltration (CR) 127
Tietjen, Gretchen E. (coauthor) see **Fagan, Susan C.,** 1299
Tilson, Hugh H. (coeditor) see **Hartzema, Abraham G.,** 85, 296, 418, 857, 1113, 1259, 1374
Timm, David M. (author) Duragesic Package Labeling (L) 1011
Tisdale, James E. (author) Pharm.D.: All or Some? (L) 680
Tolbert, Sandra R. (coauthor) see **Fuller, Matthew A.,** 36
Touchette, Mark A. (author) book review, 104; (author) The Effect of Renal Failure on Hepatic Drug Clearance (A) 1214
Townsend, Raymond J. (coeditor) see **McGhan, William F.,** 80, 289, 414, 546
Toy, Connie (author) Clonidine for Growth Acceleration (DIAS) 1339
Tramont, Edmund C. (coauthor) see **Bjornson, Darrel C.,** 414
Trope, Angela E. (coauthor) see **Bryson, Scott M.,** 68
Tutag-Lehr, Victoria (author) Intravenous Enalaprilat Therapy for Hypertension (SR) 25

U-Z

Uber, Lynn A. (coauthor) see **Nicolau, David P.,** 873
Uber, Walter E. (author) In Vivo Inactivation of Tobramycin by Piperacillin (SR) 357
Udeani, George O. (coauthor) see **Mohindra, Subodh K.,** 735
Ueno, Kazuyuki (author) Effect of a Light Breakfast on the Bioavailability of Sustained-Release Nifedipine (L) 317; (author) Mechanism of Interaction Between Theophylline and Mexiletine (RPR) 727; (author) Phenytoin–Tizanidine Interaction (L) 1273
Ujhelyi, Michael R. (author) Monitoring Serum Digoxin Concentrations During Digoxin Immune Fab Therapy (RPR) 1047
Umstead, Greg S. (author) Local Tissue Reaction to Intravenous Fluorouracil and Leucovorin (SR) 249
Usala, Anton-Lewis (author) Clonidine Therapy for Short Stature: Can the Question Be Put to Rest? (E) 1384
van der Aa, Geert C. (coauthor) see **Pouwels, Marie-Jose M.,** 1043
Van Dyke, Don C. (author) Differences in Phenytoin Biotransformation and Susceptibility to Congenital Malformations: A Review (PED) 987
Van Haecht, Chris H. (coauthor) see **Vander Stichele, Robert H.,** 1002
Vanscoy, Gordon J. (coauthor) see **Schlicht, John R.,** 1396
Van Slooten, Andrea D. (author) Combined Use of Ciprofloxacin and Sucralfate (RPR) 578
Vander Stichele, Robert H. (author) Attitude of the Public Toward Technical Package Inserts for Medication Information in Belgium (IR) 1002
Vanscoy, Gordon J. (author) Warfarin and the International Normalized Ratio: Reducing Interlaboratory Effects (TC) 1190
Vehe, Kathryn L. (coauthor) see **Broyles, Joyce E.,** 119
Verger, Guillem (coauthor) see **Zara, Corinne,** 662
Vial, Thierry (coauthor) see **Schott, Anne Marie,** 600
Vidal, C. (author) Hypersensitivity to Clindamycin (L) 317
Vidal, Pilar (coauthor) see **Duque, Alberto,** 1009
Villa, J. Sole (coauthor) see **Canals, Antonio Mirada,** 1269
Vitillo, Josephine A. (author) Preventing Medication Prescribing Errors (O) 1388
Vlasses, Peter H. (coauthor) see **Hatoum, Hind T.,** 208; (coauthor) see **Ujhelyi, Michael R.,** 1047
Volf, Nora (author) Leukemia in Bipolar Mood Disorder: Is Lithium Contraindicated? (TC) 948
Vree, Tom B. (author) Pharmacist–Physician Interaction: A Battle of Genes (O) 1132
Wagner, John G. (author) Seventy Years in Retrospect (SC) 1265
Wallace, Robert B. (coauthor) see **Semla, Todd P.,** 410
Wallander, Kay A. (coauthor) see **Chan, C.Y. Jennifer,** 130
Wandres, Daniel L. (coauthor) see **Heidorn, Lisa,** 606; (coeditor) see **Hart, Linda L.,** 30, 137, 253, 361, 473, 606, 747, 941, 1076
Warbasse, Lawrence H. (coauthor) see **Albrecht, Lisa M.,** 713
Warkentin, Theodore E. (author) Comment: Attribution of Blame in Drug-Induced Thrombocytopenia (L) 874
Wasan, Suman M. (author) Phosphate Binders in Hyperphosphatemia of Chronic Renal Failure (DIAS) 942
Waterhouse, Janette (coauthor) see **Rue, Peter J.,** 438
Watling, Sharon M. (coauthor) see **Benson, Jill M.,** 272
Watson, William A. (author) Activated Charcoal and Acetylcysteine Absorption: Issues in Interpreting Pharmacokinetic Data (TC) 1081; (author) Lidocaine Absorption and Metabolism After Oropharyngeal Application in Young and Young-Elderly Adults (SR) 463; (coauthor) see **Dolgin, Jill G.,** 646
Weber, D. Raymond (author) Is Heparin Really Necessary in the Lock and, If So, How Much? (A) 399
Webster, Kathy D. (coauthor) see **Lee, Connie R.,** 1092
Weksler, Babette B. (author) Naproxen-Induced Recurrent Aseptic Meningitis (SR) 1183
Welch, K. Michael A. (coauthor) see **Fagan, Susan C.,** 1299
Welty, Timothy E. (author) Eternal Significance (L) 215
West, Dennis P. (coauthor) see **Rumsfield, Jean A.,** 381
Whaley, Robert (coauthor) see **Lee, Connie R.,** 1092
Whelan, Anne Marie (author) Optimizing Drug Delivery from Metered-Dose Inhalers (PA) 638
White, Eugene V. (author) Comment: Origins of Clinical Pharmacy (L) 1142
White, Roger L. (coauthor) see **Uber, Walter E.,** 357
Whitney, Harvey A.K., Jr. (author) A Sketch of Donald E. Francke: Founder and First Editor (SC) 425; (author) Editor's Note: John Wagner introduction, 1265; (author) Editor's Reply: We Use Drugs Too—More Pediatric Information in Review Articles (L) 559; (author) Reborn at Age 25 (E) 97
Wiehl, Wendy (author) Vitamin E as an Anticonvulsant (DIAS) 362
Willett, Michael S. (author) book review, 683
Williams, Dennis M. (author) Comment: Ranitidine Does Not Inhibit Theophylline Metabolism (L) 1140
Williams, Karl G. (author) Update on the Right to Refuse Antipsychotic Medication (A) 849
Wilton, John H. (coauthor) see **Van Slooten, Andrea D.,** 578; (coauthor) see **Watson, William A.,** 463
Wojtynek, Jeff (coauthor) see **Shwed, Jill A.,** 10
Wolfe, Jonathan J. (coauthor) see **Ackerman, Bruce H.,** 840
Wong, Laura (author) Midazolam Routes of Administration (DIAS) 476
Wong, Roberta J. (author) book review, 879
Woodson, Gary T. (coauthor) see **Johnson, Richard E.,** 730
Wordell, Cindy J. (author) Use of Intravenous Immune Globulin Therapy: An Overview (DSP) 805
Wright, Jackson T., Jr. (coauthor) see **McKenney, James M.,** 234
Wu, Tuck S. (coauthor) see **Chow, Moses S.S.,** 613
Wulf, Patrick H. (coauthor) see **Foran, Robert M.,** 546
Yamashita, Toyoko S. (coauthor) see **Reed, Michael D.,** 344
Yamauchi, Kazutaka (coauthor) see **Ueno, Kazuyuki,** 317
Yamazaki, Kunio (coauthor) see **Ueno, Kazuyuki,** 317
Yao, Lillian J. (author) Niacinamide for Bullous Pemphigoid (DIAS) 1187
Yedinak, Kimberly C. (author) Felodipine: A New Dihydropyridine Calcium-Channel Antagonist (FF) 1193
Yishar, Uzi (coauthor) see **Oren, Ran,** 315
Yoshihara, Ryosuke (coauthor) see **Shiozawa, Shunichi,** 101
Yousuf, Mohammad J. (coauthor) see **Erickson, Steven R.,** 1178
Zahaykevich, Adrienne (author) Amiloride for Lung Disease in Cystic Fibrosis (DIAS) 1340
Zara, Corinne (author) Use of Restricted Antibiotics in Primary Care (IR) 662
Zarowitz, Barbara J. (author) Human Monoclonal Antibody Against Endotoxin (FF) 778; (coauthor) see **Robert, Sylvie,** 169; (coauthor) see **Tisdale, James E.,** 680; (coauthor) see **Ujhelyi, Michael R.,** 1047
Zeisler, John A. (author) Correction: Figures Transposed (L) 1017
Zenk, Karin E. (coauthor) see **Colbert, James Jr.,** 559
Zhanel, George G. (author) The Postantibiotic Effect: A Review of In Vitro and In Vivo Data (A) 153; (coauthor) see **Ariano, Robert E.,** 478
Zimmermann, Anthony E. (author) Probable Famotidine-Induced Thrombocytopenia (L) 678
Zolnouni, Parvaneh P. (coauthor) see **Cutler, Neal R.,** 471

ADVERTISER INDEX

American Society of Hospital Pharmacists, International Pharmaceutical Abstracts, 2, 880, 1159
Amgen Inc., Epogen, obc-Jun, ifc-Jul, obc-Sep, 1163; Neupogen, 540, 688, 902, 912, 1119, 1239, 1407
Bristol-Myers Squibb Co., Paraplatin, ifc-Jan, ifc-Mar, ifc-May; Pravachol, ifc-Dec
Burroughs Wellcome Co., Exosurf, 755, 1019; Nuromax, 485, 673, 719
Centocor, Specializing in monoclonal antibody medicine, obc-Feb, obc-Apr
Eli Lilly and Company, Everywhere!, 9, ifc-Feb, 326, ifc-Apr, 571, ifc-Jun, 904, ifc-Sep, ifc-Oct, obc-Nov

Genentech, Inc., Activase, 65, 467, 553, 589, 693, 791
Glaxo Pharmaceuticals, Ceptaz, 330, 444, 566
Harvey Whitney Books Company, A Casebook in Social and Behavioral Pharmacy, 417, 703, 1006, 1156; **Books, journals, and reprints for pharmacy and pharmacotherapy,** 690, 893, 1024, 1282, 1423; **CA/CTF,** subscription, 35, 324, 339, 477, 685, 712, 911, 1091, ibc-Nov, 1328; **Current Problems, Potential Solutions,** 163, 271, 852, 1320; **DICP, The Annals of Pharmacotherapy,** back issues, 47, 264, 538, 616, 777, 1001, 1070, 1177, 1333, bound volumes, 13, 116, ibc-Feb, 230, 314, 342, 435, 568, 576, 706, 754, 910, 1042, 1162, 1298, classified advertising, 110, FAX reprint service, 190, 387, 612, 718, 940, PharmaCE, 64, 118, 329, 577, 889, 907, 1148, 1281,1406, subscriptions, 116, 230, 342, 568, 576, 706, 910, 1042, 1162, 1298; **DRUGCALC,** 301; **Drug Therapy and Pharmacy Books, Journals, and Reprints,** 4, 224, 336; **journal of Pharmacy Technology,** reprints, 204, 283, 407, 672, 804, 1118, 1276, 1383; **L'Informatore Farmaceutico,** 892; **Medical Abbreviations,** 252, 1080, 1180, 1367; **Medifore,** 1149, 1429; **Pediatric Drug Formulations,** 178, 398, 539, 605, 856, 1112, 1213, 1387; **Peptides, Peptoids, and Proteins,** 343, 472, 634, 839, 961, 1224, 1348; **Pharmacoepidemiology,** 423, 524, 601, 896, ibc-Sept, 1192, 1378; **Principles of Pharmacoeconomics,** 40, 115, 325, ibc-Apr, 552, 667, 891, 977, 1131, 1268, 1325; **Psychotropic Drug Handbook,** 573, 707, 1039, ifc-Nov, 1295; **Research Design and Analysis,** 163, 1320; **SIMKIN Handbook of Therapeutic Monitoring,** 139, 256, 366, 539, 637, 772, 947, 1061, 1189, 1373; **The Practice of Pharmacy,** 89, 210, 888, 992
Miles Inc., Cipro, ibc-Jan, ibc-Mar, ibc-May, ibc-Jul, ibc-Oct, ibc-Dec
Personnel Placement, California, Pharmaceutical Care Network, 447, Stanford University Hospital, 699, University of Southern California, 447, University of the Pacific, 447 1419; **Canada,** Ontario, Ontario Cancer Institute, 112, Wellesley Hospital, 1288; **Connecticut,** Hartford Hospital, 1153, Medical Education Programs, 1035, 1286; **Florida,** Jackson Memorial Hospital, 897, Memorial Hospital, 900, Tampa General Hospital, 221; **Georgia,** Mercer University, 1422; **Idaho,** Idaho State University, 1420; **Illinois,** Abbott Laboratories, 334, 1035, Ernst & Young, 1036, Methodist Medical Center of Illinois, 699, Michael Reese Hospital and Medical Center, 111; **Indiana,** Methodist Hospital, 1033, St. Elizabeth Hospital, 700; **Iowa,** University of Iowa, 569, 898, 899, University of Iowa Hospitals and Clinics, 901; **Kansas,** Veterans Administration Medical Center, 1154; **Kentucky,** University of Kentucky, 698, 699, 1035; **Louisiana,** Xavier University of Louisiana, 1286; **Massachusetts,** Northeastern University, 1421, 1422; **Michigan,** Detroit Receiving Hospital and University Health Center, 1153, 1288, Ferris State University, 1033, MidMichigan Regional Medical Center, 569, University of Michigan, 1034, Wayne State University, 111, 1419, 1420, 1421, 1422; **Minnesota,** St. Paul-Ramsey Medical Center, 898; **Missouri,** University of Missouri Hospital and Clinics, 1033, University of Missouri—Kansas City, 333 1420; **Montana,** University of Montana, 1287; **Nebraska,** University of Nebraska Medical Center, 1153; **New Jersey,** Hoechst-Roussel Pharmaceuticals, 698, 901, Merck Sharp & Dohme, 697, Overlook Hospital, 698, Rutgers University, 1032, The Prudential, 334, 1034; **New York,** Albany College of Pharmacy, 447, 900, Arnold and Marie Schwartz College of Pharmacy, 449, Memorial Sloan-Kettering Cancer Center, 700, Norwich Eaton, 111, St. John's University, 1421, Vassar Brothers Hospital, 1419; **North Carolina,** Charlotte Area Health Education Center, 1287, Moses H. Cone Memorial Hospital, 1422; **North Dakota,** St. Alexius Medical Center, 1285; **Ohio,** Akron City Hospital, 898, St. Vincent Medical Center, 898, Toledo Hospital, 899, 1289, Western Reserve Care System, 334; **Oregon,** Oregon State University, 112; **Pennsylvania,** Allentown Hospital-Lehigh Valley Hospital Center, 700, Pharmacists for Life, 449, 697, 1289, SmithKline Beecham, 1036, Temple University, 1419; Thomas Jefferson University Hospital, 221; **Rhode Island,** University of Rhode Island, 112; **South Carolina,** Medical University of South Carolina Medical Center, 333, 449, 700, 900, 901, 1034, 1154, 1287; **South Dakota,** Rapid City Regional Hospital, 1032; **Tennessee,** Blount Memorial Hospital, 1288; **Texas,** University of Texas at Austin, 1421, University of Texas Health Science Center at San Antonio, 110, 221; **Utah,** University of Utah Hospital, 899; **Virginia,** Department of Veterans Affairs, 113, 222, 335, 448, 570, ibc-Jun; **Washington,** Washington State University at Spokane, 1286
Ross Laboratories, Survanta, 1031, 1155
Sandoz—Schering-Plough, GM-CSF, 454, 686, 710, 1012
Simkin, Inc., Reshaping Pharmacy Practice Through Computer Technology, 48, 306, 656, 890, 1143
Upjohn, Zefazone, 1150, 1290, 1426

INDEX ABBREVIATIONS

A:	Article
CC:	Critical Care Therapeutics
CR:	Pharmacotherapy Case Reports
DIAS:	Drug Information Analysis Service
DIR:	Drug Interactions and Reactions Update
DSP:	Drug Selection Perspectives
E:	Editorial
FF:	Formulary Forum
G:	Geriatrics and Gerontology
ibc:	inside back cover
ifc:	inside front cover
IR:	International Reports
L:	Letters
NC:	News and Comments
O:	An Opinion
obc:	outside back cover
PA:	Pulmonary and Allergy
PEC:	Pharmacoeconomics
PED:	Pediatrics
PEP:	Pharmacoepidemiology
RC:	Rho Chi Lecture
RPR:	Research/Practice Reports
SC:	Special Contributions
SR:	Short Reports
TC:	Therapeutic Controversies
TM:	Therapeutic Monitoring

Statement of ownership, management, and monthly circulation (12 issues, $100 annually) of *DICP, The Annals of Pharmacotherapy*, publication no. 00126578. Owner, Harvey Whitney Books Company. Publisher, editor, and managing editor: Harvey A.K. Whitney, Jr. Headquarters of publisher, owner, and publication: 8044 Montgomery Road, P.O. Box 42696, Cincinnati, OH 45242. Known bondholders, mortgagees, and other security holders: none. Average no. of copies each issue from October 90 to September 91 and no. of copies of September 91: A. total no. copies printed (net press run) 8021, 8000; B. paid circulation (1) single copy sales 0, 0; (2) mail subscription 6306, 6088; C. total paid circulation 6306, 6088; D. free distribution 1160, 1272; E. total distribution (C + D) 7466, 7360; F. office use, left over, etc. 555, 640; G. total (E + F) 8021, 8000. No. of issues published annually: 12. Date of filing: 27 September 1991. Signed: Harvey A.K. Whitney, Jr., Publisher.